Bortezomib (PS-341)

Name: Bortezomib (PS-341)
Brand: Selleck Chemicals
SKU: S1013
Rating: 5 (731 reviews)

For research use only.

Catalog No.S1013 Synonyms: Velcade, LDP-341, MLM341, NSC 681239

731 publications

CAS No. 179324-69-7

Bortezomib (PS-341, Velcade, LDP-341, MLM341, NSC 681239) is a potent 20S proteasome inhibitor with K_i of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells. Bortezomib (PS-341) inhibits NF-κB and induces ERK phosphorylation to suppress cathepsin B and inhibit the catalytic process of autophagy in ovarian cancer and other solid tumors.

Selleck's Bortezomib (PS-341) has been cited by 731 publications

Nature, 2021, 10.1038/s41586-020-03118-2

PubMed: 33442055 ( click the link to review the publication )

Science, 2020, eabd0811

PubMed: 33243852 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Stem Cell, 2020, 7;26(5):755-765 e7

PubMed: 32386556 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):371-386

PubMed: 32109374 ( click the link to review the publication )

Nature, 2019, 567(7747):262-266

PubMed: 30842662 ( click the link to review the publication )

Science, 2019, 363(6429)

PubMed: 30792274 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 35(1):46-63

PubMed: 30581152 ( click the link to review the publication )

Nature, 2018, 560(7718):325-330

PubMed: 30089904 ( click the link to review the publication )

Nat Med, 2018, 24(4):497-504

PubMed: 29457796 ( click the link to review the publication )

Nat Med, 2018, 24(3):292-303

PubMed: 29400713 ( click the link to review the publication )

Nature, 2017, 550(7677):534-538

PubMed: 29045385 ( click the link to review the publication )

Science, 2017, eaal3755

PubMed: 28302793 ( click the link to review the publication )

Cell, 2017, 171(5):1094-1109

PubMed: 29149604 ( click the link to review the publication )

Nat Med, 2017, 23(9):1055-1062

PubMed: 28805822 ( click the link to review the publication )

Cancer Discov, 2017, 7(3):302-321

PubMed: 28108460 ( click the link to review the publication )

Cancer Cell, 2017, 32(6):748-760

PubMed: 29232553 ( click the link to review the publication )

Nat Med, 2014, 20(6):599-606

PubMed: 24813251 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):242-52

PubMed: 22862949 ( click the link to review the publication )

Sci Adv, 2021, 7(23)eabg2697

PubMed: 34088671 ( click the link to review the publication )
Sci Adv, 2021, 7(3)eabc6364

PubMed: 33523898 ( click the link to review the publication )

Mol Plant, 2021, S1674-2052(21)00084-8

PubMed: 33711490 ( click the link to review the publication )

J Clin Invest, 2021, 146893

PubMed: 34061780 ( click the link to review the publication )

Clin Cancer Res, 2021, clincanres.1010.2021

PubMed: 34168048 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2021, 118(17)e2023157118

PubMed: 33827988 ( click the link to review the publication )

Biomaterials, 2021, 271:120720

PubMed: 33639563 ( click the link to review the publication )

Leukemia, 2021, 10.1038/s41375-021-01326-x

PubMed: 34193976 ( click the link to review the publication )

Theranostics, 2021, 11(9):4381-4402

PubMed: 33754067 ( click the link to review the publication )

Theranostics, 2021, 11(9):4281-4297

PubMed: 33754061 ( click the link to review the publication )

Theranostics, 2021, 11(5):2364-2380

PubMed: 33500730 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

Mol Cancer, 2021, 20(1):84

PubMed: 34090465 ( click the link to review the publication )

Elife, 2021, 10e65962

PubMed: 33890572 ( click the link to review the publication )

Haematologica, 2021, 10.3324/haematol.2021.278743

PubMed: 34162179 ( click the link to review the publication )

Nanoscale, 2021, 13(19):8976-8990

PubMed: 33973606 ( click the link to review the publication )

Redox Biol, 2021, 45:102045

PubMed: 34167028 ( click the link to review the publication )

Oncogene, 2021, 40(23):4004-4018

PubMed: 34007022 ( click the link to review the publication )

Oncogene, 2021, 40(25):4291-4306

PubMed: 34079090 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):201

PubMed: 34154657 ( click the link to review the publication )

Cancers (Basel), 2021, 13(4)843

PubMed: 33671345 ( click the link to review the publication )

Cell Death Dis, 2021, 12(7):624

PubMed: 34135313 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):52

PubMed: 33414430 ( click the link to review the publication )

Cell Death Dis, 2021, 12(3):229

PubMed: 33658484 ( click the link to review the publication )

Cells, 2021, 10(5)1185

PubMed: 34066177 ( click the link to review the publication )
Cells, 2021, 10(4)741

PubMed: 33801779 ( click the link to review the publication )

FASEB J, 2021, 35(2):e21284

PubMed: 33484475 ( click the link to review the publication )

Mol Cancer Ther, 2021, 10.1158/1535-7163.MCT-20-0831

PubMed: 34045230 ( click the link to review the publication )

Front Cell Dev Biol, 2021, 9:670145

PubMed: 34079802 ( click the link to review the publication )

Cell Oncol (Dordr), 2021, 10.1007/s13402-021-00590-4

PubMed: 33646559 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2021, S0167-4889(21)00073-2

PubMed: 33811937 ( click the link to review the publication )

J Cell Sci, 2021, 134(7)jcs254201

PubMed: 33712450 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(3)1341

PubMed: 33572814 ( click the link to review the publication )

Sci Rep, 2021, 11(1):2074

PubMed: 33483574 ( click the link to review the publication )

Sci Rep, 2021, 11(1):7259

PubMed: 33790333 ( click the link to review the publication )

Vascul Pharmacol, 2021, S1537-1891(21)00002-1

PubMed: 33422688 ( click the link to review the publication )

Cell Signal, 2021, 85:110068

PubMed: 34197957 ( click the link to review the publication )

Anal Biochem, 2021, 628:114286

PubMed: 34119487 ( click the link to review the publication )

Cell Biol Int, 2021, 10.1002/cbin.11557

PubMed: 33501756 ( click the link to review the publication )

Blood Adv, 2021, 5(10):2467-2480

PubMed: 33999145 ( click the link to review the publication )

Blood Adv, 2021, 5(9):2391-2402

PubMed: 33950175 ( click the link to review the publication )

Biomedicines, 2021, 9(1)E33

PubMed: 33406639 ( click the link to review the publication )

Blood Adv, 2021, 5(7):1933-1946

PubMed: 33821992 ( click the link to review the publication )

JCI Insight, 2021, 141518

PubMed: 33476303 ( click the link to review the publication )

Viruses, 2021, 13(1)E83

PubMed: 33435377 ( click the link to review the publication )

Research Square, 2021, 10.21203/rs.3.rs-265240/v1

PubMed: None ( click the link to review the publication )

Theranostics, 2021, 11(5):2364-2380

PubMed: 33500730 ( click the link to review the publication )

Oncol Rep, 2021, 45(4)34

PubMed: 33649855 ( click the link to review the publication )

Blood, 2020, 18 pii: blood

PubMed: 32187357 ( click the link to review the publication )
Adv Sci (Weinh), 2020, 7(21):2001018

PubMed: 33173725 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(23):2001914

PubMed: 33304752 ( click the link to review the publication )

Mol Cell, 2020, 5;77(5):1092-1106 e9

PubMed: 31973889 ( click the link to review the publication )

Nat Commun, 2020, 22;11(1):1931

PubMed: 32321912 ( click the link to review the publication )

Autophagy, 2020, 10.1080/15548627.2020.1740529

PubMed: 32164484 ( click the link to review the publication )

Autophagy, 2020, 18;1-13

PubMed: 32186434 ( click the link to review the publication )

EMBO J, 2020, e105071

PubMed: 32840892 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.2853.2020

PubMed: 33310890 ( click the link to review the publication )

Leukemia, 2020, 10.1038/s41375-020-01034-y

PubMed: 32879426 ( click the link to review the publication )

Leukemia, 2020, 18

PubMed: 32424294 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(33):20004-20014

PubMed: 32747568 ( click the link to review the publication )

Clin Cancer Res, 2020, 27 pii: clincanres

PubMed: 32341033 ( click the link to review the publication )

Theranostics, 2020, 10(8):3366-3381

PubMed: 32206096 ( click the link to review the publication )

Blood Cancer J, 2020, 10(12):125

PubMed: 33318477 ( click the link to review the publication )

Cell Rep, 2020, 12;31(6):107632

PubMed: 32402277 ( click the link to review the publication )

Cell Rep, 2020, 3;30(9):2948-2962 e4

PubMed: 32130899 ( click the link to review the publication )

Cell Death Differ, 2020, 10.1038/s41418-020-00649-z

PubMed: 33110214 ( click the link to review the publication )

Redox Biol, 2020, 20;101465

PubMed: 32473993 ( click the link to review the publication )

Oncogene, 2020, 9

PubMed: 32388539 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1183-x

PubMed: 32034308 ( click the link to review the publication )

Cell Mol Life Sci, 2020, 10.1007/s00018-020-03568-x

PubMed: 32607595 ( click the link to review the publication )

Sci Signal, 2020, 13(649)eaba5665

PubMed: 32934076 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 9;39(1):105

PubMed: 32517809 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3335

PubMed: 33187254 ( click the link to review the publication )
Cancers (Basel), 2020, 30;12(4):831

PubMed: 32235588 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32235770 ( click the link to review the publication )

Cancers (Basel), 2020, 11;12(5):E1207

PubMed: 32403415 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):796

PubMed: 32968046 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):701

PubMed: 32839432 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):783

PubMed: 32951004 ( click the link to review the publication )

J Clin Med, 2020, 9(2)

PubMed: 32085480 ( click the link to review the publication )

Cells, 2020, 9(11)E2357

PubMed: 33114738 ( click the link to review the publication )

FASEB J, 2020, 34(9):12379-12391

PubMed: 32960474 ( click the link to review the publication )

Cell Chem Biol, 2020, 18 pii: S2451-9456(20)30117-3

PubMed: 32386596 ( click the link to review the publication )

Pain, 2020, 161(1):177-184

PubMed: 31490328 ( click the link to review the publication )

Front Immunol, 2020,

PubMed: 32903557 ( click the link to review the publication )

Oncoimmunology, 2020, 9(1):1831153

PubMed: 33110706 ( click the link to review the publication )

Curr Biol, 2020, S0960-9822(20)31156-8

PubMed: 32857970 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12853

PubMed: 33188726 ( click the link to review the publication )

Clin Sci (Lond), 2020, CS20201038

PubMed: 33289516 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:44

PubMed: 32117974 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:575903

PubMed: 33520979 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:605989

PubMed: 33392195 ( click the link to review the publication )

Aging (Albany NY), 2020, 16;12(8):6611-6629

PubMed: 32298237 ( click the link to review the publication )

Respirology, 2020, 10.1111/resp.13867

PubMed: 32512637 ( click the link to review the publication )

Cancer Sci, 2020, 111(4):1279-1290

PubMed: 32058648 ( click the link to review the publication )

J Immunol, 2020, 205(10):2583-2594

PubMed: 33067378 ( click the link to review the publication )
FEBS J, 2020, 10.1111/febs.15675

PubMed: 33340237 ( click the link to review the publication )

Antioxidants (Basel), 2020, 9(12)E1300

PubMed: 33353055 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:117

PubMed: 32117764 ( click the link to review the publication )

J Cell Sci, 2020, jcs.241356

PubMed: 32546533 ( click the link to review the publication )

J Virol, 2020, 6;94(2) pii: e01173-19

PubMed: 31619561 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(9):5260-5273

PubMed: 32227582 ( click the link to review the publication )

Biochem Pharmacol, 2020, S0006-2952(20)30604-3

PubMed: 33333074 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(21)E7905

PubMed: 33114380 ( click the link to review the publication )

Sci Rep, 2020, 27;10(1):5562

PubMed: 32221318 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.015398

PubMed: 33082144 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00544-w

PubMed: 33139838 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

J Immunother, 2020, 43(9):265-272

PubMed: 32842039 ( click the link to review the publication )

Mol Cell Biol, 2020, MCB.00269-20

PubMed: 33168699 ( click the link to review the publication )

Cell Cycle, 2020, 19;1-12

PubMed: 32423265 ( click the link to review the publication )

Int J Biochem Cell Biol, 2020, 122:105734

PubMed: 32119989 ( click the link to review the publication )

Toxicol In Vitro, 2020, 104928

PubMed: 32622998 ( click the link to review the publication )

Mol Cells, 2020, 31;43(1):23-33

PubMed: 31870133 ( click the link to review the publication )

Eur J Pharmacol, 2020, 875:173050

PubMed: 32142770 ( click the link to review the publication )

Int J Mol Med, 2020, 45(6):1661-1672

PubMed: 32236619 ( click the link to review the publication )

Saudi J Biol Sci, 2020, 27(8):2157-2163

PubMed: 32714042 ( click the link to review the publication )

PLoS One, 2020, 15(6):e0232068

PubMed: 32559187 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 8;521(2):414-419

PubMed: 31672277 ( click the link to review the publication )
G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

SLAS Discov, 2020, 19;2472555220915851

PubMed: 32425084 ( click the link to review the publication )

Cell Biol Int, 2020, 10.1002/cbin.11322

PubMed: 32068318 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Mol Biol Rep, 2020, 47(6):4849-4856

PubMed: 32424523 ( click the link to review the publication )

Technol Cancer Res Treat, 2020, 19:1533033820948060

PubMed: 32924793 ( click the link to review the publication )

Turk J Haematol, 2020, 37(3):167-176

PubMed: 32160736 ( click the link to review the publication )

Hematology, 2020, 25(1):424-432

PubMed: 33191863 ( click the link to review the publication )

Haematologica, 2020, 10.3324/haematol.2019.227215

PubMed: 31919082 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.1232.2020

PubMed: 32669378 ( click the link to review the publication )

EMBO Mol Med, 2020, e11793

PubMed: 32720440 ( click the link to review the publication )

Cancer Rep (Hoboken), 2020, e1267

PubMed: 32706923 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Oncotarget, 2020, 11(7):727-739

PubMed: 32133047 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):89

PubMed: 32653014 ( click the link to review the publication )

RNA Biol, 2020, 10.1080/15476286.2020.1813439

PubMed: 32819190 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01408-7

PubMed: 32733069 ( click the link to review the publication )

Genes Chromosomes Cancer, 2020, 10.1002/gcc.22884

PubMed: 32614991 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01191-y

PubMed: 33250513 ( click the link to review the publication )

Mol Cells, 2020, 43(11):935-944

PubMed: 33168788 ( click the link to review the publication )

Artif Cells Nanomed Biotechnol, 2020, 48(1):735-745

PubMed: 32272856 ( click the link to review the publication )

J Leukoc Biol, 2020, 107(1):105-112

PubMed: 31729784 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2020, 202009137

PubMed: 32788348 ( click the link to review the publication )

Cancer Lett, 2020, 475:99-108

PubMed: 32014459 ( click the link to review the publication )

Nat Metab, 2020, 10.1038/s42255-020-0252-3

PubMed: 32778834 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9):E2341

PubMed: 32825035 ( click the link to review the publication )

Oncotarget, 2020, 11(44):3984-3997

PubMed: 33216827 ( click the link to review the publication )

Autophagy, 2020, 1-17

PubMed: 32762399 ( click the link to review the publication )

J Virol, 2020, JVI.01604-20

PubMed: 32817219 ( click the link to review the publication )

Cell Rep, 2020, 32(2):107897

PubMed: 32668248 ( click the link to review the publication )

Hematology, 2020, 25(1):424-432

PubMed: 33191863 ( click the link to review the publication )

FEBS J, 2020, 10.1111/febs.15480

PubMed: 32648994 ( click the link to review the publication )

Oncotarget, 2020, 11(44):3984-3997

PubMed: 33216827 ( click the link to review the publication )

Cells, 2020, 9(2)

PubMed: 32102381 ( click the link to review the publication )

Gastroenterology, 2019, 157(6):1615-1629

PubMed: 31446059 ( click the link to review the publication )

Hepatology, 2019, 10.1002/hep.31059

PubMed: 31808574 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Nat Commun, 2019, 10(1):273

PubMed: 30655516 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4184

PubMed: 31519875 ( click the link to review the publication )

Sci Adv, 2019, 5(2):eaau7130

PubMed: 30775435 ( click the link to review the publication )

Autophagy, 2019, 15(11):1954-1969

PubMed: 30894069 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1635380

PubMed: 31242129 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e9930

PubMed: 31476112 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0525-6

PubMed: 31358854 ( click the link to review the publication )

Leukemia, 2019, 33(1):171-180

PubMed: 30026574 ( click the link to review the publication )

Dev Cell, 2019, 50(1):11-24.e10

PubMed: 31130353 ( click the link to review the publication )
Dev Cell, 2019, 50(6):690-703.e6

PubMed: 31378590 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(6):2200-2209

PubMed: 30674681 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31138526 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31484670 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.212266

PubMed: 31101754 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):28

PubMed: 30717817 ( click the link to review the publication )

Kidney Int, 2019, 95(3):611-623

PubMed: 30685098 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31142515 ( click the link to review the publication )

Cancer Res, 2019, 79(21):5536-5549

PubMed: 31530568 ( click the link to review the publication )

Cell Rep, 2019, 27(6):1657-1665

PubMed: 31067453 ( click the link to review the publication )

Cell Rep, 2019, 29(5):1249-1260

PubMed: 31665637 ( click the link to review the publication )

J Control Release, 2019, 306:149-164

PubMed: 31121280 ( click the link to review the publication )

Elife, 2019,

PubMed: 31741433 ( click the link to review the publication )

Elife, 2019, 8e44161

PubMed: 30860482 ( click the link to review the publication )

Elife, 2019, 8e48469

PubMed: 31516121 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.45457

PubMed: 30907729 ( click the link to review the publication )

Haematologica, 2019, 103324/haematol2019216986

PubMed: 31123029 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32615

PubMed: 31390487 ( click the link to review the publication )

Oncogene, 2019, 38(16):3047-3060

PubMed: 30617306 ( click the link to review the publication )

mBio, 2019, 10(2)e00668-19

PubMed: 31015330 ( click the link to review the publication )

mBio, 2019, 10(3)

PubMed: 31088925 ( click the link to review the publication )

Am J Transplant, 2019, 19(3):724-736

PubMed: 30102844 ( click the link to review the publication )

Cancer Lett, 2019, 442:233-241

PubMed: 30419344 ( click the link to review the publication )

J Med Chem, 2019, 62(15):7042-7057

PubMed: 31271281 ( click the link to review the publication )
Cancers (Basel), 2019, 11(7)

PubMed: 31315220 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31756922 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)E85

PubMed: 30646520 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)E236

PubMed: 30781685 ( click the link to review the publication )

Cancers (Basel), 2019,

PubMed: 31466401 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31771104 ( click the link to review the publication )

PLoS Pathog, 2019, 15(1):e1007498

PubMed: 30645648 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):324

PubMed: 30975979 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):781

PubMed: 31611552 ( click the link to review the publication )

Cell Death Discov, 2019, 5:131

PubMed: 31482012 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.06.006

PubMed: 31303577 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(11):1544-1558.e6

PubMed: 31522999 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(3):340-351

PubMed: 30612952 ( click the link to review the publication )

Cell Physiol Biochem, 2019, 53(6):999-1014

PubMed: 31838790 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(7):1205-1216

PubMed: 31092565 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-18-1319

PubMed: 31594826 ( click the link to review the publication )

Hum Mutat, 2019, 40(4):392-403

PubMed: 30609140 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(11):3624-3638

PubMed: 31170093 ( click the link to review the publication )

Mol Neurobiol, 2019, 56(3):1653-1664

PubMed: 29916141 ( click the link to review the publication )

Neoplasia, 2019, 21(7):653-664

PubMed: 31132676 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:1659468

PubMed: 31281566 ( click the link to review the publication )

ACS Infect Dis, 2019, 5(12):2105-2117

PubMed: 31644867 ( click the link to review the publication )
Eur J Med Chem, 2019, 166:65-74

PubMed: 30684871 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(8):1622-1634

PubMed: 31497346 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2019, 1866(10):1544-1555

PubMed: 31326539 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2019, 1866(2):252-263

PubMed: 30445147 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786

PubMed: 31540997 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

J Immunol, 2019, 202(10):2849-2855

PubMed: 30936292 ( click the link to review the publication )

Mol Cancer Res, 2019,

PubMed: 31409628 ( click the link to review the publication )

Front Oncol, 2019, 9:958

PubMed: 31632904 ( click the link to review the publication )

Front Oncol, 2019, 9:722

PubMed: 31440466 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(8):5390-5402

PubMed: 31140729 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(7):838-850

PubMed: 30865564 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Antimicrob Agents Chemother, 2019, 63(9)

PubMed: 31307977 ( click the link to review the publication )

Talanta, 2019, 199:32-39

PubMed: 30952265 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(20)

PubMed: 31635163 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(3)

PubMed: 30736330 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(24)

PubMed: 31817163 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7901

PubMed: 31133683 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):2443

PubMed: 30792442 ( click the link to review the publication )

Sci Rep, 2019, 9(1):6915

PubMed: 31061434 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7779

PubMed: 31123282 ( click the link to review the publication )
Sci Rep, 2019, 9(1):14394

PubMed: 31591429 ( click the link to review the publication )

Sci Rep, 2019, 9(1):18409

PubMed: 31804603 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7199

PubMed: 31076590 ( click the link to review the publication )

Sci Rep, 2019, 9(1):18062

PubMed: 31792264 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

J Biol Chem, 2019, 294(40):14562-14573

PubMed: 31371451 ( click the link to review the publication )

J Biol Chem, 2019,

PubMed: 30523157 ( click the link to review the publication )

Food Chem Toxicol, 2019, 131:110537

PubMed: 31150782 ( click the link to review the publication )

Apoptosis, 2019, 24(1-2):184-197

PubMed: 30498998 ( click the link to review the publication )

Gene, 2019, 707:86-92

PubMed: 31071385 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:8711-8720

PubMed: 31576173 ( click the link to review the publication )

Cancer Commun (Lond), 2019, 39(1):81

PubMed: 31796105 ( click the link to review the publication )

Int J Oncol, 2019, 55(2):499-512

PubMed: 31268156 ( click the link to review the publication )

Cell Signal, 2019, 59:76-84

PubMed: 30878517 ( click the link to review the publication )

Cell Signal, 2019, 62:109351

PubMed: 31260799 ( click the link to review the publication )

J Cell Biochem, 2019, 120(3):3243-3258

PubMed: 30362618 ( click the link to review the publication )

Am J Transl Res, 2019, 11(7):4139-4150

PubMed: 31396324 ( click the link to review the publication )

Biochimie, 2019, 162:46-54

PubMed: 30946948 ( click the link to review the publication )

Molecules, 2019, 24(5)

PubMed: 30818834 ( click the link to review the publication )

Oncol Rep, 2019, 42(1):35-42

PubMed: 31115546 ( click the link to review the publication )

Oncol Rep, 2019, 41(3):1678-1690

PubMed: 30664164 ( click the link to review the publication )

ChemMedChem, 2019, 14(23):2005-2022

PubMed: 31675179 ( click the link to review the publication )

PLoS One, 2019, 14(11):e0225145

PubMed: 31703099 ( click the link to review the publication )

PLoS One, 2019, 14(12):e0225977

PubMed: 31826021 ( click the link to review the publication )
Biochem Biophys Res Commun, 2019, 514(4):1140-1146

PubMed: 31103265 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:11383-11391

PubMed: 31920329 ( click the link to review the publication )

Leuk Lymphoma, 2019, 10.1080/10428194.2019.1616190

PubMed: 31111763 ( click the link to review the publication )

Leuk Res, 2019, 78:3-11

PubMed: 30641417 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Naunyn Schmiedebergs Arch Pharmacol, 2019, 392(4):461-466

PubMed: 30554340 ( click the link to review the publication )

Methods Enzymol, 2019, 619:145-159

PubMed: 30910019 ( click the link to review the publication )

Iran J Pharm Res, 2019, 18(Suppl1):119-131

PubMed: 32802093 ( click the link to review the publication )

Cell Rep, 2019, 28(12):3167-3181.e6

PubMed: 31533039 ( click the link to review the publication )

J Blood Med, 2019, 10:105-109

PubMed: 31043801 ( click the link to review the publication )

Oncotarget, 2019, 10(28):2709-2721

PubMed: 31105871 ( click the link to review the publication )

Oncotarget, 2019, 10(63):6781-6790

PubMed: 31827721 ( click the link to review the publication )

Toxicol Forensic Med, 2019, 4(1):13-17

PubMed: 32149269 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2019, 1863(6):1108-1115

PubMed: 30974160 ( click the link to review the publication )

Blood Adv, 2019, 3(1):51-62

PubMed: 30617217 ( click the link to review the publication )

Mol Cell, 2018, 70(5):906-919

PubMed: 29804830 ( click the link to review the publication )

Mol Cell, 2018, 72(5):862-874

PubMed: 30318442 ( click the link to review the publication )

J Clin Invest, 2018, 128(7):2877-2893

PubMed: 29863498 ( click the link to review the publication )

J Clin Invest, 2018, 128(10):4682-4696

PubMed: 30198908 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )

Nat Commun, 2018, 9(1):502

PubMed: 29402884 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4514

PubMed: 30375513 ( click the link to review the publication )

Nat Commun, 2018, 9(1):672

PubMed: 29445180 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )
Autophagy, 2018, 14(6):958-971

PubMed: 29561705 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6408-6420

PubMed: 30126942 ( click the link to review the publication )

Leukemia, 2018, 32(1):139-148

PubMed: 28663576 ( click the link to review the publication )

Cancer Res, 2018, 78(5):1155-1168

PubMed: 29259009 ( click the link to review the publication )

Theranostics, 2018, 8(9):2348-2360

PubMed: 29721084 ( click the link to review the publication )

Kidney Int, 2018, 93(3):670-680

PubMed: 29229189 ( click the link to review the publication )

Blood Cancer J, 2018, 8(11):105

PubMed: 30409995 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2018, 10(26):21825-21835

PubMed: 29897225 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):29

PubMed: 29482577 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):112

PubMed: 30180865 ( click the link to review the publication )

Oncogene, 2018, 37(33):4581-4598

PubMed: 29748621 ( click the link to review the publication )

Oncogene, 2018, 37(38):5221-5232

PubMed: 29849118 ( click the link to review the publication )

Oncogene, 2018, 37(3):363-376

PubMed: 28945225 ( click the link to review the publication )

Cancer Lett, 2018, 420:156-167

PubMed: 29410067 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

J Cereb Blood Flow Metab, 2018, 38(11):1924-1939

PubMed: 29972341 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):512

PubMed: 29724992 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):162

PubMed: 29415982 ( click the link to review the publication )

PLoS Genet, 2018, 14(1):e1007165

PubMed: 29370161 ( click the link to review the publication )

Oncoimmunology, 2018, 7(10):e1484981

PubMed: 30288346 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):1871-1880

PubMed: 29959200 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1416-1429

PubMed: 29703842 ( click the link to review the publication )

J Mol Cell Cardiol, 2018, 116:16-28

PubMed: 29371135 ( click the link to review the publication )

Mol Oncol, 2018, 12(12):2124-2135

PubMed: 30259640 ( click the link to review the publication )
Oncogenesis, 2018, 7(9):75

PubMed: 30250021 ( click the link to review the publication )

J Cell Physiol, 2018, 233(5):4258-4271

PubMed: 29057477 ( click the link to review the publication )

J Cell Sci, 2018, 131(14)jcs216671

PubMed: 29930081 ( click the link to review the publication )

Lab Invest, 2018, 98(6):708-714

PubMed: 29540860 ( click the link to review the publication )

Biochem Pharmacol, 2018, 156:291-301

PubMed: 30149015 ( click the link to review the publication )

Sci Rep, 2018, 8(1):671

PubMed: 29330435 ( click the link to review the publication )

J Biol Chem, 2018, 293(4):1178-1191

PubMed: 29183995 ( click the link to review the publication )

J Biol Chem, 2018, 293(7):2452-2465

PubMed: 29279332 ( click the link to review the publication )

Mar Drugs, 2018, 16(12)

PubMed: 30572618 ( click the link to review the publication )

J Ethnopharmacol, 2018, 220:220-227

PubMed: 29097252 ( click the link to review the publication )

Exp Cell Res, 2018, 371(2):353-363

PubMed: 30149001 ( click the link to review the publication )

Exp Cell Res, 2018, 369(1):120-128

PubMed: 29772221 ( click the link to review the publication )

Cell Cycle, 2018, 17(5):568-579

PubMed: 28976232 ( click the link to review the publication )

J Mol Endocrinol, 2018, 60(2):45-54

PubMed: 29191827 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):432

PubMed: 29661248 ( click the link to review the publication )

Int Immunopharmacol, 2018, 54:39-45

PubMed: 29100036 ( click the link to review the publication )

Molecules, 2018, 23(12)

PubMed: 30567313 ( click the link to review the publication )

Mol Cells, 2018, 41(12):1008-1015

PubMed: 30396235 ( click the link to review the publication )

Oncol Rep, 2018, 39(6):2873-2880

PubMed: 29693175 ( click the link to review the publication )

Oncol Rep, 2018, 40(6):3714-3724

PubMed: 30272343 ( click the link to review the publication )

Eur J Pharmacol, 2018, 830:17-25

PubMed: 29680228 ( click the link to review the publication )

Oncol Res, 2018, 26(3):421-429

PubMed: 28899456 ( click the link to review the publication )

Biosci Rep, 2018, 38(5)

PubMed: 30177525 ( click the link to review the publication )

Dis Markers, 2018, 2018:3810108

PubMed: 30647797 ( click the link to review the publication )
Biochem Biophys Res Commun, 2018, 501(1):286-292

PubMed: 29729272 ( click the link to review the publication )

G3 (Bethesda), 2018, 8(7):2193-2204

PubMed: 29735526 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 505(1):126-133

PubMed: 30236985 ( click the link to review the publication )

J Bone Miner Metab, 2018, 36(5):537-546

PubMed: 29027021 ( click the link to review the publication )

Ann Diagn Pathol, 2018, 32:28-34

PubMed: 29414394 ( click the link to review the publication )

Target Oncol, 2018, 13(6):779-793

PubMed: 30446871 ( click the link to review the publication )

J Exp Med, 2018, 215(5):1301-1313

PubMed: 29703731 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29423101 ( click the link to review the publication )

Oncotarget, 2018, 9(23):16521-16532

PubMed: 29662664 ( click the link to review the publication )

Viruses, 2018, 10(10)

PubMed: 30261679 ( click the link to review the publication )

Oncotarget, 2018, 9(5):6450-6462

PubMed: 29464084 ( click the link to review the publication )

Leuk Res, 2018, 64:34-41

PubMed: 29175379 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Biochem Pharmacol, 2018, 156:291-301

PubMed: 30149015 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29861856 ( click the link to review the publication )

J Mol Cell Cardiol, 2018, 116:16-28

PubMed: 29371135 ( click the link to review the publication )

Blood, 2017, 5;129(1):88-99

PubMed: 27784673 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1692

PubMed: 29167449 ( click the link to review the publication )

Nat Commun, 2017, 8:15244

PubMed: 28489076 ( click the link to review the publication )

Nat Commun, 2017, 8:15676

PubMed: 28607490 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1391

PubMed: 29123089 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(4):1012-1024

PubMed: 28151717 ( click the link to review the publication )

Leukemia, 2017, 31(7):1570-1581

PubMed: 27890927 ( click the link to review the publication )

Cancer Immunol Res, 2017, 5(10):839-846

PubMed: 28903971 ( click the link to review the publication )
Cancer Res, 2017, 77(22):6282-6298

PubMed: 28978635 ( click the link to review the publication )

Cancer Res, 2017, 77(11):2927-2937

PubMed: 28404587 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3084-3096

PubMed: 27993968 ( click the link to review the publication )

Cell Mol Immunol, 2017, 10.1038/cmi.2017.8

PubMed: 28690324 ( click the link to review the publication )

Genomics Inform, 2017, 15(3):87-97

PubMed: 29020724 ( click the link to review the publication )

Cancer Lett, 2017, 405:63-72

PubMed: 28716527 ( click the link to review the publication )

J Pathol, 2017, 241(4):534-546

PubMed: 27976373 ( click the link to review the publication )

Cell Death Dis, 2017, 8(2):e2585

PubMed: 28151478 ( click the link to review the publication )

Exp Mol Med, 2017, 49(8):e365

PubMed: 28798402 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28108597 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2375-2386

PubMed: 28878026 ( click the link to review the publication )

Br J Haematol, 2017, 179(5):756-771

PubMed: 29048129 ( click the link to review the publication )

J Cancer, 2017, 8(5):839-851

PubMed: 28382147 ( click the link to review the publication )

Epigenetics, 2017, 12(2):105-112

PubMed: 27935420 ( click the link to review the publication )

J Virol, 2017, 91(12)e00554-17

PubMed: 28404849 ( click the link to review the publication )

Biochem Pharmacol, 2017, 143:118-128

PubMed: 28642038 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2685

PubMed: 28578393 ( click the link to review the publication )

Sci Rep, 2017, 7(1):5423

PubMed: 28710427 ( click the link to review the publication )

Sci Rep, 2017, 7:44700

PubMed: 28304377 ( click the link to review the publication )

Am J Pathol, 2017, 187(12):2775-2787

PubMed: 28919113 ( click the link to review the publication )

J Biol Chem, 2017, 292(30):12542

PubMed: 28754767 ( click the link to review the publication )

J Biol Chem, 2017, 292(28):11970-11979

PubMed: 28588027 ( click the link to review the publication )

J Biol Chem, 2017, 292(21):8933-8947

PubMed: 28341744 ( click the link to review the publication )

J Biol Chem, 2017, 292(30):12542

PubMed: 28754767 ( click the link to review the publication )
Endocrinology, 2017, 158(4):1005-1014

PubMed: 28323983 ( click the link to review the publication )

Endocrinology, 2017, 158(10):3097-3108

PubMed: 28938421 ( click the link to review the publication )

Biomed Pharmacother, 2017, 88:562-568

PubMed: 28131096 ( click the link to review the publication )

BMC Genomics, 2017, 18(1):127

PubMed: 28166733 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Cell Signal, 2017, 32:124-132

PubMed: 28161489 ( click the link to review the publication )

Mol Brain, 2017, 10(1):7

PubMed: 28196470 ( click the link to review the publication )

Life Sci, 2017, 173:36-42

PubMed: 28212825 ( click the link to review the publication )

BMC Cancer, 2017, 17(1):366

PubMed: 28545541 ( click the link to review the publication )

Neurotox Res, 2017, 32(4):555-562

PubMed: 28612296 ( click the link to review the publication )

Transl Oncol, 2017, 10(4):632-640

PubMed: 28668761 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 488(2):400-406

PubMed: 28502636 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(12):2916-2925

PubMed: 28509582 ( click the link to review the publication )

Cancer Genomics Proteomics, 2017, 14(1):35-51

PubMed: 28031236 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):494-506

PubMed: 28346091 ( click the link to review the publication )

Oncol Lett, 2017, 13(2):647-654

PubMed: 28356941 ( click the link to review the publication )

Journal of Functional Foods, 2017, 31:217-228

PubMed: None ( click the link to review the publication )

Cancer Metab, 2017, 5:7

PubMed: 28855983 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114698-114709

PubMed: 29383113 ( click the link to review the publication )

Oncotarget, 2017, 8(9):14604-14619

PubMed: 28099937 ( click the link to review the publication )

Oncotarget, 2017, 9(3):2984-3000

PubMed: 29423023 ( click the link to review the publication )

Cell, 2017, 170(5):860-874

PubMed: 28803730 ( click the link to review the publication )

Oncotarget, 2017, 8(46):80109-80123

PubMed: 29113288 ( click the link to review the publication )
Cell, 2017, 169(6):1105-1118

PubMed: 28575672 ( click the link to review the publication )

Cell Mol Immunol, 2017, 10.1038/cmi.2017.8

PubMed: 28690324 ( click the link to review the publication )

Hepatology, 2017, 66(3):855-868

PubMed: 28439950 ( click the link to review the publication )

Sci Rep, 2017, 7(1):682

PubMed: 28386133 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56243-56254

PubMed: 28915587 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52445-52456

PubMed: 28881742 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(2):202-12

PubMed: 26655835 ( click the link to review the publication )

Sci Transl Med, 2016, 8(339):339ra70

PubMed: 27194728 ( click the link to review the publication )

Hepatology, 2016, 64(1):161-74

PubMed: 26926206 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:12368

PubMed: 27492902 ( click the link to review the publication )

Nat Commun, 2016, 7:13150

PubMed: 27748395 ( click the link to review the publication )

Autophagy, 2016, 12(4):632-47

PubMed: 27050454 ( click the link to review the publication )

EMBO J, 2016, 35(23):2602-2613

PubMed: 27789522 ( click the link to review the publication )

Dev Cell, 2016, 37(1):15-33

PubMed: 27052834 ( click the link to review the publication )

Leukemia, 2016, 30(4):861-72

PubMed: 26658839 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(32):9015-20

PubMed: 27450084 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(46):13162-13167

PubMed: 27799547 ( click the link to review the publication )

Genes Dev, 2016, 30(24):2684-2695

PubMed: 28087713 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3531-40

PubMed: 27197154 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(5):1222-33

PubMed: 26527748 ( click the link to review the publication )

Plant Cell, 2016, 28(6):1279-96

PubMed: 27194708 ( click the link to review the publication )

Matrix Biol, 2016, 55:22-34

PubMed: 27016342 ( click the link to review the publication )

Blood Cancer J, 2016, 6(8):e462

PubMed: 27564460 ( click the link to review the publication )
Blood Cancer J, 2016, 6(7):e446

PubMed: 27421095 ( click the link to review the publication )

Cell Rep, 2016, 16(1):120-132

PubMed: 27320908 ( click the link to review the publication )

Oncogene, 2016, 35(38):4973-80

PubMed: 26973240 ( click the link to review the publication )

Cancer Lett, 2016, 372(1):82-8

PubMed: 26721204 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

PLoS Pathog, 2016, 12(10):e1005929

PubMed: 27706223 ( click the link to review the publication )

Lab Chip, 2016, 16(2):334-44

PubMed: 26660268 ( click the link to review the publication )

J Neurosci, 2016, 36(6):1930-41

PubMed: 26865616 ( click the link to review the publication )

Cell Death Dis, 2016, 7(12):e2492

PubMed: 27906188 ( click the link to review the publication )

FASEB J, 2016, 30(2):923-32

PubMed: 26546130 ( click the link to review the publication )

Expert Opin Drug Deliv, 2016, 13(8):1075-81

PubMed: 27087021 ( click the link to review the publication )

Br J Haematol, 2016, 173(1):70-81

PubMed: 26729247 ( click the link to review the publication )

Dis Model Mech, 2016, 9(11):1317-1328

PubMed: 27519691 ( click the link to review the publication )

Mol Biol Cell, 2016, 27(8):1272-85

PubMed: 26941331 ( click the link to review the publication )

Am J Pathol, 2016, 186(3):678-90

PubMed: 26801735 ( click the link to review the publication )

J Biol Chem, 2016, 291(31):16162-74

PubMed: 27302064 ( click the link to review the publication )

J Biol Chem, 2016, 291(45):23719-23733

PubMed: 27621311 ( click the link to review the publication )

J Biol Chem, 2016, 291(29):15082-92

PubMed: 27226596 ( click the link to review the publication )

J Biol Chem, 2016, 291(2):939-47

PubMed: 26527686 ( click the link to review the publication )

Int J Oncol, 2016, 49(5):1848-1858

PubMed: 27601063 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(9):966-75

PubMed: 27434731 ( click the link to review the publication )

Eur J Pharmacol, 2016, 791:99-104

PubMed: 27568836 ( click the link to review the publication )

Eur J Cell Biol, 2016, 95(10):389-400

PubMed: 27567537 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0150044

PubMed: 26982031 ( click the link to review the publication )
PLoS One, 2016, 11(12):e0168193

PubMed: 27978543 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0150484

PubMed: 26930278 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(7):1677-86

PubMed: 26421357 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(11):2644-52

PubMed: 26980288 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Target Oncol, 2016, 11(6):783-798

PubMed: 27250763 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):546-57

PubMed: 27029345 ( click the link to review the publication )

Oncotarget, 2016, 7(11):12254-66

PubMed: 26930721 ( click the link to review the publication )

Oncotarget, 2016, 7(47):77622-77634

PubMed: 27769058 ( click the link to review the publication )

Oncotarget, 2016, 7(4):4559-69

PubMed: 26683226 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(3):1161-78

PubMed: 26578593 ( click the link to review the publication )

Oncotarget, 2016, 7(47):77326-77341

PubMed: 27764795 ( click the link to review the publication )

Oncotarget, 2016, 7(25):38523-38538

PubMed: 27229530 ( click the link to review the publication )

Oncotarget, 2016, 7(2):1323-40

PubMed: 26593250 ( click the link to review the publication )

Oncotarget, 2016, 7(4):4062-76

PubMed: 26716651 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2016, 95(2):751-60

PubMed: 27045812 ( click the link to review the publication )

Sarcoma, 2016, 2016:3484673

PubMed: 27822137 ( click the link to review the publication )

Oncotarget, 2016, 7(4):4454-67

PubMed: 26683357 ( click the link to review the publication )

Drug Discov Ther, 2016, 10(4):195-200

PubMed: 27594296 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71790-71801

PubMed: 27708243 ( click the link to review the publication )

Oncotarget, 2016, 7(2):1598-607

PubMed: 26624982 ( click the link to review the publication )

Oncotarget, 2016, 7(47):77622-77634

PubMed: 27769058 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45214-45224

PubMed: 27286258 ( click the link to review the publication )

Oncotarget, 2016, 7(4):4559-69

PubMed: 26683226 ( click the link to review the publication )
Oncotarget, 2016, 7(43):70845-70856

PubMed: 27683126 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45214-45224

PubMed: 27286258 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26824319 ( click the link to review the publication )

Oncotarget, 2016, 7(43):70845-70856

PubMed: 27683126 ( click the link to review the publication )

Oncotarget, 2016, 7(48):78883-78895

PubMed: 27713151 ( click the link to review the publication )

Oncotarget, 2016, 7(38):62572-62584

PubMed: 27613836 ( click the link to review the publication )

Mol Cells, 2016, 39(12):898-908

PubMed: 28008160 ( click the link to review the publication )

Sci Rep, 2016, 6:28528

PubMed: 27339427 ( click the link to review the publication )

FASEB J, 2016, 30(2):923-32

PubMed: 26546130 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(7):917-29

PubMed: 26075355 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-1462

PubMed: 25748087 ( click the link to review the publication )

Leukemia, 2015, 29(6):1390-401

PubMed: 25533804 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-14-2109

PubMed: 25712341 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(20):4663-75

PubMed: 26116270 ( click the link to review the publication )

Biomaterials, 2015, 73:70-84

PubMed: 26402156 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

Cell Rep, 2015, 12(4):622-35

PubMed: 26190113 ( click the link to review the publication )

J Control Release, 2015, 211:44-52

PubMed: 26031842 ( click the link to review the publication )

Elife, 2015, 4:e08153

PubMed: 26327694 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.455

PubMed: 25619841 ( click the link to review the publication )

Oncogene, 2015, 34(16):2138-2144

PubMed: 24909167 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

J Clin Endocrinol Metab, 2015, 100(5):E697-709

PubMed: 25675381 ( click the link to review the publication )

J Dent Res, 2015, 94(9):1243-50

PubMed: 26130255 ( click the link to review the publication )
Br J Haematol, 2015,

PubMed: 26310606 ( click the link to review the publication )

Structure, 2015, 23(2):407-17

PubMed: 25599643 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(2):639-50

PubMed: 25973303 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: ( click the link to review the publication )

J Immunol, 2015, 194(4):1695-701

PubMed: 25560410 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: 25582703 ( click the link to review the publication )

Traffic, 2015, 10.1111/tra.12287

PubMed: 25824657 ( click the link to review the publication )

J Virol, 2015, 89(5):2643-58

PubMed: 25520503 ( click the link to review the publication )

J Virol, 2015, 89(5):2643-58

PubMed: ( click the link to review the publication )

Toxicol Sci, 2015, 10.1093/toxsci/kfv056

PubMed: 25766884 ( click the link to review the publication )

Sci Rep, 2015, 5:18251

PubMed: 26671574 ( click the link to review the publication )

Sci Rep, 2015, 5:13001

PubMed: 26306624 ( click the link to review the publication )

J Biol Chem, 2015, 290(50):29854-68

PubMed: 26483548 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(2):639-650

PubMed: ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 283(1):1-8

PubMed: 25576094 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25817892 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):474-86

PubMed: 25422130 ( click the link to review the publication )

Phys Chem Chem Phys, 2015, 17(29):18971-9

PubMed: 26126833 ( click the link to review the publication )

Cell Signal, 2015, 27(10):1939-48

PubMed: 26163823 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):474-86

PubMed: ( click the link to review the publication )

BMC Cancer, 2015, 15:738

PubMed: 26483043 ( click the link to review the publication )

BMC Cancer, 2015, 15:444

PubMed: 26025442 ( click the link to review the publication )

Toxicol In Vitro, 2015, 29(8):1965-76

PubMed: 26165741 ( click the link to review the publication )

Biomed Rep, 2015, 3(6):797-801

PubMed: 26623018 ( click the link to review the publication )
Biosci Rep, 2015, 35(6)

PubMed: 26500282 ( click the link to review the publication )

Malar J, 2015, 14(1):200

PubMed: 25968882 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134825

PubMed: 26284517 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:417586

PubMed: 26539491 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Int J Hematol, 2015, 102(5):569-78

PubMed: 26341959 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43540-56

PubMed: 26498353 ( click the link to review the publication )

J Bio Mater Res, 2015, 103(4):1476-84

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(38):40704-18

PubMed: 26513019 ( click the link to review the publication )

Oncotarget, 2015, 6(35):38079-92

PubMed: 26472030 ( click the link to review the publication )

Oncotarget, 2015, 6(28):26347-58

PubMed: 26267322 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(10):8200-9

PubMed: 25860931 ( click the link to review the publication )

Chem Biol, 2015, 10.1016/j.chembiol.2015.01.004

PubMed: 25728267 ( click the link to review the publication )

Oncotarget, 2015, 6(37):40141-57

PubMed: 26472029 ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(10):8418-29

PubMed: 25762625 ( click the link to review the publication )

Oncotarget, 2015, 6(10):8200-9

PubMed: 25860931 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(28):26347-58

PubMed: 26267322 ( click the link to review the publication )

Oncotarget, 2015, 6(1):56-70

PubMed: 25474141 ( click the link to review the publication )

Oncotarget, 2015, 6(17):14953-69

PubMed: 25879451 ( click the link to review the publication )
Sci Transl Med, 2014, 6(250):250ra112

PubMed: 25143362 ( click the link to review the publication )

Blood, 2014, 20;124(22):3250-9

PubMed: 25205118 ( click the link to review the publication )

Blood, 2014, 123(26):4120-31

PubMed: 24711662 ( click the link to review the publication )

J Clin Invest, 2014, 124(9):3757-66

PubMed: 25061876 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Nat Commun, 2014, 5:3772

PubMed: 24805825 ( click the link to review the publication )

Autophagy, 2014, 10(9):1603-21

PubMed: 25046115 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(6):1576-89

PubMed: 24634471 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(16):E1591-9

PubMed: 24715725 ( click the link to review the publication )

Cancer Res, 2014, 74(16):4458-69

PubMed: 24934808 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2803-15

PubMed: 24686171 ( click the link to review the publication )

Cancer Res, 2014, 74(11):3127-36

PubMed: 24755468 ( click the link to review the publication )

J Cell Biol, 2014, 205(6):771-80

PubMed: 24934156 ( click the link to review the publication )

Cell Death Differ, 2014, 21(12):1838-51

PubMed: 25034784 ( click the link to review the publication )

Mol Cancer, 2014, 13(1):159

PubMed: 24972933 ( click the link to review the publication )

Int J Cancer, 2014, 135(12):2950-61

PubMed: 24771510 ( click the link to review the publication )

Eur J Cancer, 2014, 51(1):1-8

PubMed: 25466507 ( click the link to review the publication )

Cancer Lett, 2014, 343(2):286-94

PubMed: 24120758 ( click the link to review the publication )

Br J Cancer, 2014, 110(9):2224-31

PubMed: 24691427 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1126

PubMed: 24625985 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1580

PubMed: 25522274 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):926-37

PubMed: 24482380 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(12):3013-23

PubMed: 25253782 ( click the link to review the publication )
Mol Cell Proteomics, 2014, 13(12):3294-307

PubMed: 25128556 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

J Biomed Nanotechnol, 2014, 10(4):717-23

PubMed: 24734524 ( click the link to review the publication )

J Am Heart Assoc, 2014, 3(1):e000520

PubMed: 24572252 ( click the link to review the publication )

J Nutr Biochem, 2014, 25(5):515-25

PubMed: 24613086 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt13):2898-909

PubMed: 24806960 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 21):4728-39

PubMed: 25179605 ( click the link to review the publication )

J Virol, 2014, 87(23):13035-41

PubMed: 24027330 ( click the link to review the publication )

Eur J Immunol, 2014, 44(6):1604-14

PubMed: 24643698 ( click the link to review the publication )

J Leukocyte Biol, 2014, 95(3):461-9

PubMed: 24231258 ( click the link to review the publication )

Sci Rep, 2014, 4:6370

PubMed: 25231679 ( click the link to review the publication )

Sci Rep, 2014, 4:4164

PubMed: 24566666 ( click the link to review the publication )

Cancer Gene Ther, 2014, 21(11):472-82

PubMed: 25323693 ( click the link to review the publication )

J Biol Chem, 2014, 289(17):11906-15

PubMed: 24570003 ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14075-88

PubMed: 24711452 ( click the link to review the publication )

J Biol Chem, 2014, 289(5):2687-700

PubMed: 24337575 ( click the link to review the publication )

J Proteome Res, 2014, 13(5):2223-38

PubMed: 24669782 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(19):3570-8

PubMed: 25022755 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2014, 307(9):C774-87

PubMed: 25143351 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(10):1350-7

PubMed: 25019382 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(6):742-57

PubMed: 24618845 ( click the link to review the publication )

World J Gastroenterol, 2014, 20(48):18207-15

PubMed: 25561788 ( click the link to review the publication )

J Biomed Mater Res A, 2014, 10.1002/jbm.a.35286

PubMed: 25046528 ( click the link to review the publication )

Hematol Oncol, 2014, 10.1002/hon.2179

PubMed: 25394177 ( click the link to review the publication )
Neurotoxicology, 2014, 42:33-48

PubMed: 24705302 ( click the link to review the publication )

J Vasc Interv Radiol, 2014, 25(12):1972-82

PubMed: 25439675 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 73(1):69-77

PubMed: 24190701 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 10.1007/s00280-014-2451-7

PubMed: 24842158 ( click the link to review the publication )

PLoS One, 2014, 9(9):e103015

PubMed: 25181509 ( click the link to review the publication )

PLoS One, 2014, 9(6):e99211

PubMed: 24911872 ( click the link to review the publication )

PLoS One, 2014, 9(3):e89848

PubMed: 24595136 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107009

PubMed: 25255316 ( click the link to review the publication )

Mol Cell Biochem, 2014, 398(1-2):165-73

PubMed: 25292312 ( click the link to review the publication )

J Nanopart Res, 2014, 42:33-48

PubMed: http://link.springer.com/article/10.1007/s11051-01 ( click the link to review the publication )

Biosciences biotechnology research asia, 2014, 10.13005bbra.1309

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(13):5177-89

PubMed: 25015789 ( click the link to review the publication )

Sci Rep, 2014, 4:5896

PubMed: 25077633 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Hepatology, 2013, 57(2):625-36

PubMed: 22991197 ( click the link to review the publication )

Nat Chem Biol, 2013, 10(1):61-8

PubMed: 24292069 ( click the link to review the publication )

Nat Protoc, 2013, 8(6):1155-68

PubMed: 23702832 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(11):3019-31

PubMed: 23584492 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5591-601

PubMed: 24004671 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(1):246-51

PubMed: 23248292 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(9):3501-6

PubMed: 23382202 ( click the link to review the publication )

Cancer Res, 2013, 74(1):56-67

PubMed: 24310398 ( click the link to review the publication )

Cell Rep, 2013, 4(4):751-63

PubMed: 23954782 ( click the link to review the publication )

Mucosal Immunol, 2013, 7(4):857-68

PubMed: 24280938 ( click the link to review the publication )
Int J Cancer, 2013, 133(6):1357-67

PubMed: 23463417 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(6):R107

PubMed: 24207099 ( click the link to review the publication )

Br J Dermatol, 2013, 168(3):504-12

PubMed: 23445313 ( click the link to review the publication )

Free Rad Biol Med, 2013, 65:778-88

PubMed: 23973637 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e50

PubMed: 24158003 ( click the link to review the publication )

Pain, 2013, 154(11):2432-40

PubMed: 23891899 ( click the link to review the publication )

Expert Opin Drug Deliv, 2013, 10(10):1345-52

PubMed: 23937147 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(7):1299-309

PubMed: 23657945 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(5):747-58

PubMed: 23475956 ( click the link to review the publication )

Mol Oncol, 2013, 7(6):1012-8

PubMed: 23916134 ( click the link to review the publication )

ACS Chem Biol, 2013, 8(3):578-87

PubMed: 23198928 ( click the link to review the publication )

Gynecol Oncol, 2013, 128(2):383-90

PubMed: 23107612 ( click the link to review the publication )

FEBS J, 2013, 280(15):3609-20

PubMed: 23702335 ( click the link to review the publication )

J Virol, 2013, 87(21):11872-83

PubMed: 23986594 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(10):4456-69

PubMed: 23742826 ( click the link to review the publication )

Biochem Pharmacol, 2013, 85(11):1611-8

PubMed: 23523860 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559 ( click the link to review the publication )

J Trauma Acute Care Surg, 2013, 74(2):499-507

PubMed: 23354244 ( click the link to review the publication )

Mol Biol Cell, 2013, 35:215-22

PubMed: 24145151 ( click the link to review the publication )

Clin Exp Metastasis, 2013, 30(4):407-15

PubMed: 23412907 ( click the link to review the publication )

Retrovirology, 2013, 10(1):120

PubMed: 24156270 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2013, 139(9):1551-62

PubMed: 23877657 ( click the link to review the publication )

Toxicol Lett, 2013, 223(2):109-15

PubMed: 24055520 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 72(6):1335-42

PubMed: 24121478 ( click the link to review the publication )
Chembiochem, 2013, 14(12):1494-503

PubMed: 23881799 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73710

PubMed: 24040035 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59390

PubMed: 23527180 ( click the link to review the publication )

PLoS One, 2013, 8(9):e75280

PubMed: 24086494 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82053

PubMed: 24312627 ( click the link to review the publication )

Eur J Haematol, 2013, 91(4):339-46

PubMed: 23869695 ( click the link to review the publication )

Leuk Res, 2013, 37(10):1302-8

PubMed: 23896061 ( click the link to review the publication )

J Int Med Res, 2013, 41(5):1505-19

PubMed: 23975859 ( click the link to review the publication )

Curr Protoc Chem Biol, 2013, 5(3):195-212

PubMed: 24391083 ( click the link to review the publication )

FEBS J, 2013, 280(15):3609-20

PubMed: 23702335 ( click the link to review the publication )

Blood, 2012, 119(24):5772-81

PubMed: 22538852 ( click the link to review the publication )

Blood, 2012, 119(11):2579-89

PubMed: 22262760 ( click the link to review the publication )

Nat Struct Mol Biol, 2012, 19(4):387-94

PubMed: 22407014 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(17):4669-81

PubMed: 22806876 ( click the link to review the publication )

Br J Pharmacol, 2012, 168(8):1868-77

PubMed: 23194305 ( click the link to review the publication )

Cancer Lett, 2012, 316(1):77-84

PubMed: 22082529 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(5):1487-96

PubMed: 22377766 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e295

PubMed: 22495350 ( click the link to review the publication )

FASEB J, 2012, 26(5):1855-65

PubMed: 22345405 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(11):2321-30

PubMed: 22964485 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(10):2243-53

PubMed: 22933706 ( click the link to review the publication )

Br J Haematol, 2012, 157(6):718-31

PubMed: 22533681 ( click the link to review the publication )

J Virol, 2012, 86(18):10112-22

PubMed: 22787216 ( click the link to review the publication )

J Virol, 2012, 86(24):13360-70

PubMed: 23015717 ( click the link to review the publication )
Am J Physiol Endocrinol Metab, 2012, 303(3):E410-21

PubMed: 22669242 ( click the link to review the publication )

J Biol Chem, 2012, 287(13):10344-54

PubMed: 22318734 ( click the link to review the publication )

J Biol Chem, 2012, 288(2):1125-34

PubMed: 23209294 ( click the link to review the publication )

J Biol Chem, 2012, 288(4):2721-33

PubMed: 23209292 ( click the link to review the publication )

J Biol Chem, 2012, 287(41):34722-9

PubMed: 22910913 ( click the link to review the publication )

J Pharmacol Exp Ther, 2012, 343(1):184-97

PubMed: 22787116 ( click the link to review the publication )

Prostate, 2012, 72(10):1140-9

PubMed: 22127954 ( click the link to review the publication )

Cell Cycle, 2012, 11(9):1804-17

PubMed: 22510564 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

Biol Reprod, 2012, 87(2):44

PubMed: 22592496 ( click the link to review the publication )

PLoS One, 2012, 7(1):e29541

PubMed: 22235305 ( click the link to review the publication )

PLoS One, 2012, 7(4):e34684

PubMed: 22514654 ( click the link to review the publication )

Exp Mol Pathol, 2012, 93(1):99-110

PubMed: 22475623 ( click the link to review the publication )

Steroids, 2012, 77(11):1025-32

PubMed: 22683670 ( click the link to review the publication )

J Biomol Screen, 2012, 17(9):1231-42

PubMed: 22927676 ( click the link to review the publication )

J Biomol Screen, 2012, 17(5):572-80

PubMed: 22357874 ( click the link to review the publication )

Biochem Cell Biol, 2012, 90(2):224-31

PubMed: 22397456 ( click the link to review the publication )

Saint Louis University, 2012, 2012/0270829

PubMed: ( click the link to review the publication )

Sarcoma, 2012, 2012:805614

PubMed: 22919280 ( click the link to review the publication )

Blood, 2011, 118(14):3922-31

PubMed: 21841164 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Development, 2011, 138(14):2903-8

PubMed: 21653611 ( click the link to review the publication )

Br J Haematol, 2011, 155(5):588-98

PubMed: 21950728 ( click the link to review the publication )

J Virol, 2011, 85(6):2781-92

PubMed: 21228236 ( click the link to review the publication )
J Biol Chem, 2011, 286(18):16018-29

PubMed: 21454483 ( click the link to review the publication )

Exp Cell Res, 2011, 317(18):2671-82

PubMed: 21871886 ( click the link to review the publication )

Int Immunopharmacol, 2011, 11(12):2242-5

PubMed: 21979495 ( click the link to review the publication )

PLoS ONE, 2011,

PubMed: 21949687 ( click the link to review the publication )

PLoS One, 2011, 6(8):e23712

PubMed: 21887304 ( click the link to review the publication )

Cell Biochem Biophys, 2011, 60(3):173-85

PubMed: 21132543 ( click the link to review the publication )

University of Porto, 2011, Mireia Vila Gasull

PubMed: ( click the link to review the publication )

Glia, 2010, 58(16):1961-76

PubMed: 20830808 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

J Virol, 2010, 84(18):9439-51

PubMed: 20592098 ( click the link to review the publication )

J Biol Chem, 2010, 285(52):41074-86

PubMed: 20956535 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description

Targets

NF-κB ^[6] ()	20S proteasome ^[1] (Cell-free assay)
	0.6 nM(Ki)

In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. ^[2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
NCI-H1838	MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7FfIdFUUN3ME20NVg3NjN{IN88US=>	NFywPGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
IMR-5	NGDoT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGeyUGVKSzVyPUO0NFkvPjJizszN	NYLEfIFlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
TE-441-T	NV;DTZlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHQeINKSzVyPUK1NlEvPyEQvF2=	M2rUb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
U-698-M	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIqwcpBKSzVyPUKyOlIvOTVizszN	MkWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
COLO-824	M1P6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTETWM2OD1zMk[xMlc5KM7:TR?=	M3\KelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
P31-FUJ	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTFzMUKuO\|Uh\|ryP	NXjNZpRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
KY821	M2Ts[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTFyM{[uNFQh\|ryP	NYLGT5Y{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
RPMI-8866	NHzFSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzHfIpKSzVyPUGwNFYvOjhizszN	M4\LR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
TC-YIK	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTvRmlzUUN3ME23PFEvODFibl2=	NXja[49rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
MS-1	NGq4UIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonMTWM2OD15NUmuOFIhdk1?	MoC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
DMS-153	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFewRYxKSzVyPUe0Ok45OyCwTR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SUP-T1	M2HscGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTZ6Nj6wOEBvVQ>?	MkP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
SCC-15	NH22OYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPub\|ZKSzVyPU[2O{41PyCwTR?=	NVW4NpFZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
MSTO-211H	MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LwVWlEPTB;NUe0MlI3KG6P	NHXJfXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
J-RT3-T3-5	NVLJVIR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TDRmlEPTB;NUOyMlU4KG6P	M4qwdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H889	MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nGeGlEPTB;NE[xMlkzKG6P	MmnxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
CPC-N	M4T5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUG1d3RYUUN3ME20NFMvPzdibl2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
COLO-668	M3T4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXH2VWs4UUN3ME20NFMvPTdibl2=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H226	NITnWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDBN3RTUUN3ME20NFMvOjNibl2=	NIn0dok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
TUR	M3LEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTN7Nj62NUBvVQ>?	M33zblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
DEL	M4jN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPrTWM2OD1\|OUGuNlchdk1?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H1963	MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTN6Nj6xPUBvVQ>?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
CA46	M3;wc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknCTWM2OD1\|N{OuOlMhdk1?	MnrBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
SNU-C1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTN4Mj6wPUBvVQ>?	M2nNfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
THP-1	M2LqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTNSZh1UUN3ME2zNlIvPiCwTR?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SCH	NGXubHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFLvbJpKSzVyPUOyNk4zOiCwTR?=	NUP3Rot4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H1522	NWjVRm5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX72OVUzUUN3ME2zNFcvODVibl2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
LNCaP-Clone-FGC	M3fwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnVNIZKSzVyPUK5OU4zPiCwTR?=	NWqyPY9iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H2171	NUfLOW46T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknmTWM2OD1{OEiuPVIhdk1?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H187	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIizfoNKSzVyPUK4O{4xQCCwTR?=	NVfQcotXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
KASUMI-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrRSJVtUUN3ME2yPFMvODVibl2=	NH\LTlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
SK-MEL-2	NUm3SlkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn24TWM2OD1{OEGuPUBvVQ>?	NGXPSms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
EW-22	NYnFdZdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{T1PGlEPTB;Mk[zMlc2KG6P	NW\GRnVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H1299	Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTJ4MT63NUBvVQ>?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
COR-L279	M1vTdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjRZmFKSzVyPUK1Nk4yPyCwTR?=	M1TJbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H1155	M1;EbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTJ\|MD6zNkBvVQ>?	NVzKWm5YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H1395	NVntd21uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1e5VGlEPTB;MkGwMlE{KG6P	M2THblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
KM-H2	NFv4W4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTF7Nz6wOUBvVQ>?	NYfjc\|E6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H209	M1Pjb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjGTWM2OD1zOU[uOVIhdk1?	M3;NcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H510A	NIrwcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTF6NT6zO{BvVQ>?	NVW1UZpFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H1304	NHvYUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYqyPFdoUUN3ME2xOlkvOjFibl2=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SCLC-21H	NH3QeYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;LW3N3UUN3ME2xOVkvPDFibl2=	MkPmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H524	Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTF3OT6xJI5O	NHjDcZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
MC116	NHrDZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEP1OmhKSzVyPUG0PE45PSCwTR?=	NFzKRpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
BV-173	NGX6V3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTF{Mj63NUBvVQ>?	Ml\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
MHH-CALL-2	M4\WPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;zWWhvUUN3ME2xNVUvPyCwTR?=	NW\TeIhHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H1650	NVzDb\|BzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTFzNT6yPUBvVQ>?	M{DBdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
ST486	M3Pn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;xNolzUUN3ME2xNVQvODZibl2=	NXHGSJFlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
GR-ST	NHzxcWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rBU2lEPTB;MUGzMlM1KG6P	M1X4NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SIG-M5	MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTFyNT6wOkBvVQ>?	M3vMWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H1770	M3X1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDDS20xUUN3ME2xNFIvPDlibl2=	NFrVSXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
RH-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7Q[WtKSzVyPUm5Mlg2KG6P	M2jqcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
AM-38	NGfOd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3UTWM2OD16OD6wPEBvVQ>?	M{C2UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
RL	NVjDdpdRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjKfldKSzVyPUi2MlA6KG6P	M4X4[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
CAL-148	NWPFZ49ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3nbINnUUN3ME24NU45PCCwTR?=	Ml:1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
SK-N-FI	NUjFT2pZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRThyLkKgcm0>	M2jTUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
EW-11	MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TNTGlEPTB;N{iuOVIhdk1?	M2jIO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
EW-13	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXr2[HZQUUN3ME23O{44PiCwTR?=	M{fvWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
ALL-PO	NELxVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofoTWM2OD15Nz62OkBvVQ>?	NX3kPHhCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
KP-N-YS	MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHmTWM2OD15Nj63OEBvVQ>?	NWj3e45NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
KMS-12-PE	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXWTWM2OD15Nj6yOEBvVQ>?	M3TOblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H128	NVLicXVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3jPFNKSzVyPUe0Mlc4KG6P	NXe5b\|FTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H322M	M2LzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3sPHFpUUN3ME22Ok4yOSCwTR?=	NWLPZWFQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
BT-474	NYX2S3V4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTZ3IH7N	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MRK-nu-1	MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DaVGlEPTB;NkGuPFIhdk1?	NIrDR5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
YT	NWfxbIRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moi2TWM2OD14MT64JI5O	NX70dXJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
LP-1	M3XldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTqbmk3UUN3ME22NU4zQCCwTR?=	NXT4NYFxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
P30-OHK	NYT6b4VtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrpPVF2UUN3ME21OE43OSCwTR?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-N87	MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHS0ZmdKSzVyPUW0MlE5KG6P	MnTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
TALL-1	Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7KbmdjUUN3ME21N{46OSCwTR?=	NGX5TJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
MC-CAR	MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfGTWM2OD13MT61NkBvVQ>?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H720	NV7UOYMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLzUIhrUUN3ME21NU4yOSCwTR?=	MlK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
RS4-11	Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\pRZg6UUN3ME21NE45QCCwTR?=	NF\Bc2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
DMS-79	MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzOPVRHUUN3ME21NE44OSCwTR?=	MmnnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H716	MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\mTWM2OD12OD64NUBvVQ>?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
RPMI-6666	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnIV2lIUUN3ME20OU45QSCwTR?=	M3i5V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
L-428	MonES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TxOWlEPTB;NEOuPFYhdk1?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SKM-1	MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLETWM2OD12Mj62N{BvVQ>?	MlLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H2227	Mlz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M32zWGlEPTB;NECuOFkhdk1?	NIexSIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
SHP-77	NVvFRohGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTN6LkCzJI5O	NX2y[ohDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
D-283MED	NILPcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\lOGlEPTB;M{euO\|khdk1?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MDA-MB-134-VI	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHId25WUUN3ME2zOU45PyCwTR?=	M3OwZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
C8166	NXvSemlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn24TWM2OD1\|NT63JI5O	M1HhdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
UACC-812	NHnRUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTtSpdKUUN3ME2zOU41PCCwTR?=	NYPxTWtGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
ES3	NUOxVHN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTN3LkG5JI5O	M174VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SK-MEL-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTN3LkG3JI5O	NXSyfYM1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
KARPAS-422	NHm3PHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{exemlEPTB;M{WuNFQhdk1?	Mn;HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H719	NIP6VWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTN2LkOxJI5O	NHy5NHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H526	NVzIc4JpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTN{LkW0JI5O	M4DHN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
EW-3	NGDQRVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PYXGlEPTB;M{CuOVkhdk1?	M2n0eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
OCI-AML2	NHHZUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEKxU3lKSzVyPUK5MlY6KG6P	NHGwfo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
ECC4	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnf3TWM2OD1{OD63PUBvVQ>?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
WSU-NHL	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjZO4lKSzVyPUK4MlM6KG6P	M3\QbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NH-12	MkH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjPTWM2OD1{Nz62O{BvVQ>?	NEDObFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
LU-165	NUHTelZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTJ4LkeyJI5O	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
REH	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTJ4LkSxJI5O	NX3W[ldtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
LS-1034	M4\G[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jxPGlEPTB;MkWuO\|Uhdk1?	NHPmXJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
HDLM-2	NGKwflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2Hpe2lEPTB;MkSuOVQhdk1?	M3XtNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
EC-GI-10	M2HOdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1r6W2lEPTB;MkSuNlMhdk1?	M1\3VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
IM-9	M3jvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HKZmlEPTB;MkOuOVQhdk1?	NV25bJA{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
DOHH-2	NWSyZXZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrJ[Vk1UUN3ME2yN{41PSCwTR?=	NWPtdXpORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SIMA	NIX2dIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LyfmlEPTB;MkOuN\|ghdk1?	NYPx[W1jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
EW-12	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHWV4pMUUN3ME2yN{4yPyCwTR?=	M2O0b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
HCC2157	NHrRWJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13Ee2lEPTB;MkOuNVMhdk1?	NGLk[nk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H82	NES3dFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TIbWlEPTB;MkOuNFIhdk1?	M3;VVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
IST-MES1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vuemlEPTB;MkKuO\|chdk1?	M320SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H446	NF74XoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIS1Ro9KSzVyPUKxMlE5KG6P	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SF539	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrDVmlKSzVyPUKwMlY4KG6P	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
TE-6	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HTUmlEPTB;MkCuNFghdk1?	NX\mNpFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
HCC2218	MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGO2WolKSzVyPUG5MlUhdk1?	M1T1VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
DG-75	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLSWG92UUN3ME2xPE43OSCwTR?=	Mln5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCCIT	NVXqWWFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\kbWZKSzVyPUG4MlM3KG6P	M1LndlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
EoL-1-	MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTPdVdbUUN3ME2xPE4{OSCwTR?=	MnnwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
EB2	NETSSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjmSpNKSzVyPUG4MlA5KG6P	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NB14	M1H6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHvN3N[UUN3ME2xO{46QCCwTR?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
EW-18	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mor5TWM2OD1zNz65OkBvVQ>?	NIfZOGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
MFM-223	M{fGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4OxdGlEPTB;MUeuPVEhdk1?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
COLO-800	M2n6fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPMWJhJUUN3ME2xO{43PCCwTR?=	NXXnWlBwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
GOTO	M1zNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXOTWM2OD1zNz6wOkBvVQ>?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H1436	M4XOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTF5LkCxJI5O	NWS0S3hCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
U-87-MG	NH;wN5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTF4Lke2JI5O	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
TGW	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTF4LkS4JI5O	M{nwVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
JAR	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTmTWM2OD1zNj6xN{BvVQ>?	Moq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NB7	NGHGRndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTF3LkmyJI5O	MlvyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-SNU-1	NFXwT2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmD2TWM2OD1zMz6xPUBvVQ>?	NE[0coE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
JVM-3	MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTF{Lkm5JI5O	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H1581	M2XFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LKS2lEPTB;MUKuNlghdk1?	M2mzcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H23	NIL3PWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTF{LkGyJI5O	M4X5[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
HCC1599	MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkWzTWM2OD1zMT65NUBvVQ>?	MnPXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
ES5	M4DZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETOUXJKSzVyPUGwMlM5KG6P	MljWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H2081	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYr6Z\|BkUUN3ME2xNE4xQSCwTR?=	NX6yc5FORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
CTB-1	NEjjcmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;lOY5KSzVyPUmuOlchdk1?	MkH6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
DMS-114	M17LXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGH4OXJKSzVyPUmuOlIhdk1?	NFrufoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
SK-NEP-1	MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTMTWM2OD17LkCxJI5O	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
ATN-1	M1zDS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXYd4oxUUN3ME24Mlg6KG6P	M3LhSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
MLMA	NVj2[2dQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4S1cGlEPTB;OD64OUBvVQ>?	MkXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NB6	MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorsTWM2OD16LkS4JI5O	MlfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
MN-60	MoDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nVcWlEPTB;OD6xOEBvVQ>?	NFvCT5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
KG-1	MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoW1TWM2OD15Lkm0JI5O	NFXjV\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
L-363	M4f5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TOU2lEPTB;Nz63JI5O	MkPoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-SNU-16	M2nsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTdwNkWgcm0>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H1694	NGfoXoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vaeWlEPTB;Nz61PEBvVQ>?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
LU-134-A	NX3IcHBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXXTWM2OD15LkO5JI5O	NVHqepNxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
JVM-2	M{nhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTdwMkigcm0>	M1z2dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SU-DHL-1	NGK3fVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPnN4o3UUN3ME23MlI1KG6P	NY[xc49oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H345	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF3Cb4xKSzVyPUeuNkBvVQ>?	M3jNV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NB1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF25Om5KSzVyPU[uPFghdk1?	MmTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H2196	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3T6b2lEPTB;Nj64JI5O	NFKwXII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
GDM-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LKVWlEPTB;Nj63O{BvVQ>?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
BC-3	M4XLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGKzXHBKSzVyPU[uOlEhdk1?	NFWxVmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
D-502MG	M{fDfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLXeJZKSzVyPU[uN\|chdk1?	Mm[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LU-65	NHzrUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfHc4tqUUN3ME21Mlg1KG6P	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H1417	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XoPWlEPTB;NT61NUBvVQ>?	MoLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
EW-1	NEXiUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTVwM{Ggcm0>	MlnYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
SW962	NWCwNmJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1ewZWlEPTB;NT6yNUBvVQ>?	MnG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-SNU-5	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXOboxJUUN3ME21MlE4KG6P	M1\vVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
LU-139	NYfRSVdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2fSVWlEPTB;NT6xN{BvVQ>?	MlP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
CHP-126	NH;mNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHWSmVKSzVyPUWuNFYhdk1?	NVrCT5JXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SBC-1	M1rZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljWTWM2OD13LkCxJI5O	M3G3eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
JiyoyeP-2003	NEHERnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrvTWM2OD13IH7N	NUfseFF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
MHH-NB-11	MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzJTWM2OD12LkmxJI5O	M4TQe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
MHH-PREB-1	Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTRwOE[gcm0>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
IST-SL1	NWqzRWxXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2e3[mlEPTB;ND62PEBvVQ>?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
HL-60	MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXaTWM2OD12Lk[3JI5O	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NALM-6	M{\YdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfoXmtmUUN3ME20MlQ6KG6P	MkfzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
Raji	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\LWopKSzVyPUSuOFYhdk1?	NVi4W\|FORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NOMO-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTRwM{Ogcm0>	M4PpN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
TE-12	MnvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTRwMkWgcm0>	NFf4XWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
LB647-SCLC	M1LZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7me5ZLUUN3ME20MlIzKG6P	NXvZdHFvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
OMC-1	MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LBOGlEPTB;ND6xPEBvVQ>?	NVLaPVIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H1648	M1PKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTRwMUOgcm0>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
K-562	NX7XcWVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHCTWM2OD12LkGyJI5O	M1nLWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H2141	M3HNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjLSWdKSzVyPUSuNFUhdk1?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
HD-MY-Z	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlX4TWM2OD1\|LkmzJI5O	M2fUdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
RCC10RGB	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLRXmFKSzVyPUOuPVMhdk1?	NH3VXHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
COLO-320-HSR	NVrrZ\|hyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1ewVmlEPTB;Mz65NkBvVQ>?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
RL95-2	M2KzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzqTWM2OD1\|Lke5JI5O	M4D6flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
LC-1F	Mn;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\LTWlEPTB;Mz63OEBvVQ>?	NEK3V3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NMC-G1	MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4K4WGlEPTB;Mz62PEBvVQ>?	NXHIR\|RyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
COLO-684	M1jPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HV[WlEPTB;Mz62OkBvVQ>?	M4q0[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
DJM-1	M1zLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLBTWM2OD1\|Lk[zJI5O	NH7jdZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
EVSA-T	M125c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLjTWM2OD1\|Lk[gcm0>	MofoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
no-11	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DHZmlEPTB;Mz61OUBvVQ>?	MlXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
MZ1-PC	NIfCdWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7ZTIZ1UUN3ME2zMlU1KG6P	MonVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
HCC1187	MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTsS4xiUUN3ME2zMlU1KG6P	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
KARPAS-45	NVHlN5llT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLodGtKSzVyPUOuOVQhdk1?	Moj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
RPMI-8402	MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTNwNTDuUS=>	NEXTT5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
LOXIMVI	NITDO\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTNwNTDuUS=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MEG-01	MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjVTWM2OD1\|LkS5JI5O	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
LAMA-84	Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkniTWM2OD1\|LkS5JI5O	MlLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
COR-L88	M3u4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDXU4lyUUN3ME2zMlQ4KG6P	M{LvVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
TE-15	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLqeHpKUUN3ME2zMlQ{KG6P	M33INlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
DB	M4P6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PsN2lEPTB;Mz60NUBvVQ>?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
LB996-RCC	MoL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEe4eHFKSzVyPUOuOEBvVQ>?	NYT0UmdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NEC8	M4rtUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPKbZBCUUN3ME2zMlM2KG6P	MnjnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
SK-N-DZ	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTNwMk[gcm0>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
CW-2	M4jkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jOfGlEPTB;Mz6yNUBvVQ>?	NFXRS2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
SK-PN-DW	NVjD[m9jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvETWM2OD1\|LkG0JI5O	MmDyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
CGTH-W-1	NHvGRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmq0TWM2OD1\|LkGgcm0>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MONO-MAC-6	Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTFTIVEUUN3ME2zMlEhdk1?	NEj3dVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
KARPAS-299	MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTNwME[gcm0>	MkfSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
HT	NVW0VZNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrvOldKSzVyPUOuNFIhdk1?	NFn6R2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
SW954	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1vnbWlEPTB;Mj65JI5O	NYPYbJNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
MOLT-16	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnj0TWM2OD1{Lki5JI5O	NILDNXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
C2BBe1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUe0VFZYUUN3ME2yMlg6KG6P	NVrjbHlKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
ETK-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTJwOESgcm0>	NV3qNJd{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
CTV-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfyTWM2OD1{Lkigcm0>	NV3pfIZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
EW-16	NY[1cpF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jLT2lEPTB;Mj63OUBvVQ>?	NWfHdpQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
Mo-T	NGnrbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTJwN{Sgcm0>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
EB-3	Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3QTWM2OD1{Lk[2JI5O	NGfLbos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
LB1047-RCC	MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7QdnVkUUN3ME2yMlU4KG6P	M1XFRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
KNS-81-FD	NHzoTYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYW5PZBPUUN3ME2yMlQ5KG6P	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NB69	NEDNfYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrOOZdlUUN3ME2yMlQ3KG6P	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H64	NWize\|lXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTJwNESgcm0>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
KU812	NVPvdFFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFWzOVhKSzVyPUKuOFIhdk1?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H748	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPQTWM2OD1{LkO5JI5O	NYr0bldMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
ARH-77	M2DFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTJwM{igcm0>	M4TGfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SCC-3	NInMTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDSTWM2OD1{LkO3JI5O	NVqzd\|M6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
RPMI-8226	NYm2fZpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3f4e2lEPTB;Mj6zOUBvVQ>?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NB10	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTXSW1oUUN3ME2yMlMzKG6P	NGnpR2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
BC-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fwfmlEPTB;Mj6zNUBvVQ>?	MnHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NB5	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1W0NmlEPTB;Mj6yO{BvVQ>?	NUTkeIpYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
KMOE-2	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TJZmlEPTB;Mj6yN{BvVQ>?	Mn3CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
SJSA-1	MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzpboNGUUN3ME2yMlIyKG6P	M3yxfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
ES4	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPsTWM2OD1{LkG2JI5O	M3T2PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
KGN	M2n4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPyWllGUUN3ME2yMlE2KG6P	NE\yfJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
EKVX	NWHjdpZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nDc2lEPTB;Mj6xOEBvVQ>?	M{jIe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
MOLT-4	M2qzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rPWGlEPTB;Mj6xN{BvVQ>?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
KE-37	NFuwVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnFWmxxUUN3ME2yMlE{KG6P	NHLsUFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
HH	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFX4NlZKSzVyPUKuNVMhdk1?	NUf4[mtORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
GT3TKB	MoLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrwdpJ3UUN3ME2yMlEzKG6P	NXXVeWhFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
BL-70	NXrlcpJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHv0WllKSzVyPUKuNVIhdk1?	NXK5bYdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NOS-1	NF\ZNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPOTWM2OD1{LkGxJI5O	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
EW-24	NEnHPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDyOppKSzVyPUKuNFghdk1?	NEPQd3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
LAN-6	NIX2d3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjUNIxCUUN3ME2yMlA2KG6P	NU\1Sm5DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NB17	NY\V[5B5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIq0OXFKSzVyPUKuNFQhdk1?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
LS-123	NGjFeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlSxTWM2OD1{LkCyJI5O	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NB13	M1;VRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTJibl2=	Mn\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NKM-1	NFXOVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTJibl2=	NFnKbo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
697	NGn1UYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTFwOUmgcm0>	NVe2bJpsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
BE-13	M1vLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4H1TGlEPTB;MT65N{BvVQ>?	MnT4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
MPP-89	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTFwOEmgcm0>	M1;oPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
Becker	Mm[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3T6WmlEPTB;MT64N{BvVQ>?	M2C1PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
MV-4-11	NFf6bVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfkXWFNUUN3ME2xMlgzKG6P	MnH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
GB-1	NF7TNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojKTWM2OD1zLkixJI5O	M{XhPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H1092	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3QTWM2OD1zLkigcm0>	MmrnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H2126	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjuTWM2OD1zLkigcm0>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
LC4-1	MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTFwN{mgcm0>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
U-266	M{DPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITIbYZKSzVyPUGuO\|Yhdk1?	MlzCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
KURAMOCHI	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLHTWM2OD1zLkeyJI5O	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
TGBC1TKB	M2HCOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTFwN{Ggcm0>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
EHEB	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4O4W2lEPTB;MT62O{BvVQ>?	NHfHTnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
GCIY	NGDlTVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY[5[29CUUN3ME2xMlYzKG6P	NHjmTm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
HEL	NFrRe4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjuPHR6UUN3ME2xMlYyKG6P	M2fDTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NB12	NEDUTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVyyeW5sUUN3ME2xMlU3KG6P	NYLxN5I1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H69	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTFwNUSgcm0>	Mon3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LS-411N	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHGx[oVKSzVyPUGuOVMhdk1?	MkmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
PF-382	M2jsWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TGbmlEPTB;MT60O{BvVQ>?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
CAS-1	M{CzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fkU2lEPTB;MT6zO{BvVQ>?	NUfpdHBpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
L-540	M1fyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnQcHNDUUN3ME2xMlM4KG6P	NFv1WY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
ECC12	M2DldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTFwM{egcm0>	NFPyfVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
DU-4475	MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PWSGlEPTB;MT6zOkBvVQ>?	NIr5N4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
OPM-2	MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\WTWFbUUN3ME2xMlM{KG6P	NWnQZYp3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
IST-SL2	M1vEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4ju[2lEPTB;MT6zNUBvVQ>?	NXPjcGNrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
Calu-6	MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzuOWhyUUN3ME2xMlI6KG6P	MoHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
CMK	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHsfXI3UUN3ME2xMlI6KG6P	NUHNd3ZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
A3-KAW	NYPzenI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojkTWM2OD1zLkK4JI5O	MojqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
K5	M{PFbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnTFTWM2OD1zLkK4JI5O	NVnxWnhyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
KM12	NUHlemZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnvTWM2OD1zLkK3JI5O	M1z1eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SR	Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7HW\|k4UUN3ME2xMlI2KG6P	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
BL-41	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLCOIpKSzVyPUGuNlUhdk1?	NXvIRnZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
Daudi	NY\ISndST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFO5UWlKSzVyPUGuNlIhdk1?	NYnneWFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H1882	M4HwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTFwMjDuUS=>	NEXIPHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
TE-8	NEDSO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDXTWM2OD1zLkG5JI5O	NGPOOI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
HAL-01	NEPkVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTFwMUigcm0>	NEHTN2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
EM-2	NHXtVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvxTWM2OD1zLkG2JI5O	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
CCRF-CEM	Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XWdmlEPTB;MT6xN{BvVQ>?	NWXLcVFrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
D-392MG	NWP6eVI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTFwMTDuUS=>	M4PadVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
MZ7-mel	MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXqVGRKSzVyPUGuNFkhdk1?	M1HvOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
VA-ES-BJ	NI\JNVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HDc2lEPTB;MT6wPUBvVQ>?	NXnLcWNIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SK-MM-2	MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fz[WlEPTB;MT6wPUBvVQ>?	MnTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LC-2-ad	M{nKcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLsOVJKSzVyPUGuNFghdk1?	M3PSdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
RKO	NHHMZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XiR2lEPTB;MT6wOkBvVQ>?	MmLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
TE-10	NF;odI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLhWZRLUUN3ME2xMlA{KG6P	NYn5bXhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
TE-1	NHPFd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTFwMEOgcm0>	NFXZXZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
PSN1	NVrBNVhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjSbItKSzVyPUGuNFEhdk1?	NGPLVpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
SW872	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUP5eG5QUUN3ME2wMlk6PiCwTR?=	Mo\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
HC-1	MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYq5dW9qUUN3ME2wMlk4PSCwTR?=	M1m2R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
KALS-1	M{nie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\TeHVKSzVyPUCuPVI2KG6P	M{DXflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SF268	NFP6cpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jMRWlEPTB;MD65NlMhdk1?	MnvwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
IST-MEL1	NW\LSY5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PQS2lEPTB;MD65NVchdk1?	NXruWYpVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
RXF393	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTBwOUG0JI5O	NXXj[W9GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SNB75	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDIUI5tUUN3ME2wMlkyOiCwTR?=	Mn;HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H1355	M3XY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{PpPWlEPTB;MD64PVUhdk1?	MnzIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
TE-5	NWrOOVJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTBwOE[1JI5O	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
QIMR-WIL	NVLVOVVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEGyfIFKSzVyPUCuPFg6KG6P	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SK-LMS-1	NH3Fd21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrjTWM2OD1yLki1OEBvVQ>?	MmjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
SW684	NELKO4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTBwOEKxJI5O	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
ML-2	MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTBwOEKxJI5O	NEDmcpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
D-263MG	M3Tz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TlOWlEPTB;MD64NFchdk1?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
LB2241-RCC	MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTBwOEC0JI5O	MkjZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
GI-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPoXolQUUN3ME2wMlc3PCCwTR?=	NFLuem49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
ES7	NILaV\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHziPY1KSzVyPUCuO\|Y3KG6P	M3zsXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
LS-513	Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTBwN{O5JI5O	M4TFR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
KINGS-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTBwN{KyJI5O	NW\DdVJSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
UACC-257	M1zGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfpR45XUUN3ME2wMlcyKG6P	NHW4OHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
LB373-MEL-D	NUfCTWVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXmeYZKSzVyPUCuO{BvVQ>?	M{L6b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SF126	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGf3Z4RKSzVyPUCuO\|AyKG6P	NHznNo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
Ramos-2G6-4C10	MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPhTWM2OD1yLk[5N{BvVQ>?	MnzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
TK10	MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\4RWlEPTB;MD62O\|khdk1?	M4HtbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
D-336MG	NWfiUJBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHiTWM2OD1yLk[1O{BvVQ>?	MoX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
BB49-HNC	NV3ofoUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nCXmlEPTB;MD62OVIhdk1?	NIP3RW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
HOP-62	MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITXWFNKSzVyPUCuOlQ4KG6P	NFjhflE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
LB831-BLC	NGrsXVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHQc4lpUUN3ME2wMlY1OSCwTR?=	M32zcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
GI-ME-N	NX\mfFBOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXruPYRCUUN3ME2wMlY{PCCwTR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
A4-Fuk	MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\0ZXp6UUN3ME2wMlYzOyCwTR?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
HT-144	M1zVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTT[pdiUUN3ME2wMlU4PiCwTR?=	MknJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
COLO-829	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYe5NlFqUUN3ME2wMlYyPCCwTR?=	MnX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H747	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{L4WGlEPTB;MD61N\|khdk1?	NIe2b3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
CESS	NIPxXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILt[2hKSzVyPUCuOVM5KG6P	NV;SZWtURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
HUTU-80	M3TJZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGi5eGZKSzVyPUCuOVM{KG6P	M1jZSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
DSH1	Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnqwTWM2OD1yLkS4JI5O	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
LB771-HNC	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPMNlQ4UUN3ME2wMlQ4PCCwTR?=	NHHqRWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
CP66-MEL	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIK4SJhKSzVyPUCuOFc{KG6P	NXK1fG1tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
OCUB-M	M1\ER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHVfHk2UUN3ME2wMlQ1PyCwTR?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MFH-ino	Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jCZWlEPTB;MD60OFMhdk1?	NYHk[Fh5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
OS-RC-2	M1PCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYj0VXVqUUN3ME2wMlQ1KG6P	NEDBcFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
HCE-T	MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkezTWM2OD1yLkSzPUBvVQ>?	NFjOfJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
ES1	NV62[Ih6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfMc4NuUUN3ME2wMlQ{KG6P	MkXnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LB2518-MEL	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHvTWM2OD1yLkSyOUBvVQ>?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
ACN	NWLnbWQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDLUIFUUUN3ME2wMlQyPyCwTR?=	NWPiTnJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
D-247MG	NWLvSWViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTBwNEGzJI5O	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
HCC2998	MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLwTWM2OD1yLkSxNkBvVQ>?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MZ2-MEL	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjP[\|hQUUN3ME2wMlQxPyCwTR?=	Mnm4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
ES8	M1TSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPEZmp7UUN3ME2wMlQhdk1?	M4DqUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
A388	NXW0R3N1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3X0S2lEPTB;MD6zOVYhdk1?	MkjUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
KS-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTBwM{Sgcm0>	M4DnRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
BB30-HNC	MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjoVW11UUN3ME2wMlM{PSCwTR?=	NW\kV3MyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
ONS-76	M4XOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEH5e4xKSzVyPUCuN\|Mhdk1?	NY\rcWN{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
D-542MG	NGDuSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXj2[oZwUUN3ME2wMlMzQSCwTR?=	NIPaXnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
BB65-RCC	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHr2N5ZKSzVyPUCuN\|A1KG6P	MmTKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LOUCY	M17RO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPIb5dKSzVyPUCuNlk{KG6P	MkXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
OVCAR-4	NInHOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3hOI9KSzVyPUCuNlg6KG6P	MoD2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LXF-289	MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELqTZNKSzVyPUCuNlY6KG6P	NYLEfVBsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
KNS-42	M2rpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7HZ3FTUUN3ME2wMlI2QCCwTR?=	MlvwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
8-MG-BA	NGnHWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmKyTWM2OD1yLkK1JI5O	M2fpelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NTERA-S-cl-D1	NXWwSG9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPRfIo5UUN3ME2wMlI1OyCwTR?=	MofBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
A101D	MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHVRXNIUUN3ME2wMlIzPSCwTR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MMAC-SF	NF7FNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;zTWM2OD1yLkKxOkBvVQ>?	MlXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
no-10	MmHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml64TWM2OD1yLkKxJI5O	NE\DNm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
A253	NGfMT\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTBwMkC4JI5O	MlKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
TE-9	NVnKS3Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrySYRKSzVyPUCuNVgzKG6P	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SH-4	M1T4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3ITWM2OD1yLkG3N{BvVQ>?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SK-UT-1	NVnneFhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXqdZJKSzVyPUCuNVY{KG6P	NHO2e3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
ES6	NHvmXHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTBwMECyNUBvVQ>?	NY\sfVFORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
human PBMC	NFTSdZFHfW6ldHnvckBCe3OjeR?=	M{XpN\|ExOCCwTR?=	NVznXVU{OjRiaB?=		NVfaVHB6UW6mdXPld{BKVC16IILlcIVie2V?	NWTFVHhERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVE1PzdpPkK1O\|kyPDd5PD;hQi=>
U937	MX\GeY5kfGmxbjDBd5NigQ>?	MYCxNFAhdk1?	MXW2JIg>		NFLwPVJKdmS3Y3XzJGlNNThiZYjwdoV{e2mxbjDpckBNWFNvc4TpcZVt[XSnZDDVPVM4KG2jY4LvdIhi\2W\|	MlHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OUG0O\|coRjJ3N{mxOFc4RC:jPh?=
HH	NYm0fGdvVWmpcnH0bY9vKEG\|c3H5	MWCxNFAhdk1?	MWWyOEBp	MVTEUXNQ	M4TKT3Jm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MTW=	NX33PFBFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PFE{OzVpPkK1OlgyOzN3PD;hQi=>
Hut-78	MWjNbYdz[XSrb36gRZN{[Xl?	NXLhUmVHOTByIH7N	MUiyOEBp	MkPnSG1UVw>?	MYjS[YR2[2W\|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTBn	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ6MUOzOUc,OjV4OEGzN\|U9N2F-
HH	NHLJc2hHfW6ldHnvckBCe3OjeR?=	MlLSNVAxKG6P	M3j4WlI1KGh?	MUDEUXNQ	MkXX[I94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOiCneIDy[ZN{cW:w	NIDUXmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[4NVM{PSd-MkW2PFE{OzV:L3G+
H9	MmP1SpVv[3Srb36gRZN{[Xl?	NE\nZWsyODBibl2=	NXGxTYxnOjRiaB?=	MkjpSG1UVw>?	NFu4VHpFd3ewcnXneYxifGW\|IGTHSk3PujFiYX7kJGlNNTFzIHX4dJJme3Orb36=	M4nCZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkixN\|M2Lz5{NU[4NVM{PTxxYU6=
Hut-78	NHPFTmdHfW6ldHnvckBCe3OjeR?=	MmfRNVAxKG6P	NFTQSXYzPCCq	NUHk[4pITE2VTx?=	M2P4R2Rwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTBiZYjwdoV{e2mxbh?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ6MUOzOUc,OjV4OEGzN\|U9N2F-
H1299	NHfBU\|ZCeG:ydH;zbZMhSXO\|YYm=	NInyfII5OCCwTR?=	NUP6do45OjRiaB?=	MkHzSG1UVw>?	MXXT[Y5{cXSrenXzJG5US0yFIHPlcIx{KHSxIF3TR{1l\XKrdnXkJIlEQS2rbnT1Z4VlKGGyb4D0c5Nqew>?	NXP3SJZ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNlM3QTNpPkK1N\|I{Pjl\|PD;hQi=>
BLM	Ml;iRZV1d3CqYXf5JGF{e2G7	NFyxN3kyOCCwTR?=	MX6xNkBp		NHPkZpJKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:\|b33ldy=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB5OUC4N{c,OjNyN{mwPFM9N2F-
A375	NH;KSlhCfXSxcHjh[5khSXO\|YYm=	NX21Z4I1OTBibl2=	MmrJNVIhcA>?		MkT3TY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB5OUC4N{c,OjNyN{mwPFM9N2F-
BLM	M2HtbGFxd3C2b4Ppd{BCe3OjeR?=	MkfBNVAhdk1?	M3fwTVI1KGh?		NIfY[XVKdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NYfSUoZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwO\|kxQDNpPkKzNFc6ODh\|PD;hQi=>
A375	NGD5O4NCeG:ydH;zbZMhSXO\|YYm=	NGXoWZkyOCCwTR?=	NVjZ[ZRPOjRiaB?=		Mkj0TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NFnDbWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C3PVA5Oyd-MkOwO\|kxQDN:L3G+
RAW 264.7	NVLLXYFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV60bY5xOTByIH7N	M3PsRVQ5KGh?		MWnS[YR2[2W\|IHPlcIwhfmmjYnnsbZR6yqB?	NUe5WGhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0NlcyPTRpPkKyOFI4OTV2PD;hQi=>
SNK-6	M2DncGFvfGm4aYLhcEBCe3OjeR?=	MV:xJO69VQ>?	MkPKNlQhcA>?		NU\uTJlLUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY	M1fyWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUewPVg5Lz5{MUG3NFk5QDxxYU6=
KAI-3	NWnnSGZ2SW62aY\pdoFtKEG\|c3H5	NVjLeYd7OSEQvF2=	MUiyOEBp		MUnJcoR2[2W\|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY>	NX6wNJFCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO\|A6QDhpPkKxNVcxQTh6PD;hQi=>
SNT-16	MVHBcpRqfmm{YXygRZN{[Xl?	NV60WmxVOSEQvF2=	NGfp[YQzPCCq		Ml3VTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MEm4PEc,OjFzN{C5PFg9N2F-
SNT-13	M{Wwe2FvfGm4aYLhcEBCe3OjeR?=	NFj6VVAyKM7:TR?=	NEPXT3QzPCCq		M4i5dGlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>?	MmrIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzN{C5PFgoRjJzMUewPVg5RC:jPh?=
KHYG-1	NV2wNYZUSXCxcITvd4l{KEG\|c3H5	M1yyd\|Eh\|ryP	MknMOkBp		M1TIcWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	NHnoV4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3NFk5QCd-MkGxO\|A6QDh:L3G+
KAI-3	MW\BdI9xfG:\|aYOgRZN{[Xl?	NVjMR\|h1OSEQvF2=	NV\wVIdCPiCq		MnjxTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	M4LZW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUewPVg5Lz5{MUG3NFk5QDxxYU6=
Jurkat	MmHqRZBweHSxc3nzJGF{e2G7	NX7vcWNYOSEQvF2=	NGPGV\|M3KGh?		MmLyTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NYSwN3pDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO\|A6QDhpPkKxNVcxQTh6PD;hQi=>
SNT-16	M3H4WmFxd3C2b4Ppd{BCe3OjeR?=	MnXUNUDPxE1?	NXHa[ZRbPiCq		NX\WZo85UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	M1fzR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUewPVg5Lz5{MUG3NFk5QDxxYU6=
KHYG-1	M3nKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXuwTJRqOSEQvF2=	MVWyOEBp		Ml\pVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi	NHXhbZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3NFk5QCd-MkGxO\|A6QDh:L3G+
SNK-6	NVnKco1RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jHNFEh\|ryP	M4H1d\|I1KGh?		MYPS[YR2[2W\|IHPlcIwhfmmjYnnsbZR6yqB?	M37mcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUewPVg5Lz5{MUG3NFk5QDxxYU6=
KAI-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XadFEh\|ryP	M4nxNVI1KGh?		NXXIN2REWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	NHW3eGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3NFk5QCd-MkGxO\|A6QDh:L3G+
Jurkat	NGHsUohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1n1V\|Eh\|ryP	NXvyc2RrOjRiaB?=		NHLleoRT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=	NGDN[VY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3NFk5QCd-MkGxO\|A6QDh:L3G+
SNT-16	MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjtW5VxOSEQvF2=	NXTKdHlmOjRiaB?=		NXj5TXZbWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	M1S0[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUewPVg5Lz5{MUG3NFk5QDxxYU6=
SNT-13	NEPjZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDDNXIyKM7:TR?=	MkXTNlQhcA>?		MYfS[YR2[2W\|IHPlcIwhfmmjYnnsbZR6yqB?	NEXYV2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3NFk5QCd-MkGxO\|A6QDh:L3G+
BJAB	M3vSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVSyR3JoOSEQvF2=	M{\RW\|I1KGh?		NWHMd\|F4WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MEm4PEc,OjFzN{C5PFg9N2F-
LCL-2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrsNUDPxE1?	NX7aRmdwOjRiaB?=		NWPaPHVEWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	NXT6TVZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO\|A6QDhpPkKxNVcxQTh6PD;hQi=>
LCL-1	MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjyNUDPxE1?	MkfsNlQhcA>?		NEjsRmpT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=	M2iyeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUewPVg5Lz5{MUG3NFk5QDxxYU6=
Raji	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml:2NUDPxE1?	Mo\LNlQhcA>?		NEexSnFT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=	MknTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzN{C5PFgoRjJzMUewPVg5RC:jPh?=
BaF/3-p210	MmnoSpVv[3Srb36gRZN{[Xl?	NELrTpk3KG6P	NHrUbmUzPCCq		MYnS[YR2[2W\|IITo[UBxcG:\|cHjvdplt[XSrb36gZY5lKHSqZTDhZ5Rqfmm2eTDv[kBT[g>?	NUHiO5ZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzNFU3QTJpPkKwN\|A2Pjl{PD;hQi=>
BaF/3-p210	NHu1SIhHfW6ldHnvckBCe3OjeR?=	M3jLb\|Yhdk1?	MkCxOFghcA>?		NF7ZSWdKdmS3Y3XzJIEhe2yrZ3j0JGcyKGOnbHytZ5lkdGViYYLy[ZN1	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODNyNU[5Nkc,OjB\|MEW2PVI9N2F-
BaF/3	NXzwZVVoTnWwY4Tpc44hSXO\|YYm=	NIPUcFA3KG6P	MkXDOFghcA>?		M4[zWGlv\HWlZYOgZUBoemWjdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=>	NIPFXm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEOwOVY6Oid-MkCzNFU3QTJ:L3G+
TCC-S	NV7VdWc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnYXW8yODBibl2=	MnnVOFghcA>?		M4\aVWlEPTB;Mj64JI5O	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODNyNU[5Nkc,OjB\|MEW2PVI9N2F-
BaF/3-p210	NXPX[4s{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHFOWsyODBibl2=	NEX1PHE1QCCq		MV;JR\|UxRTRwNzDuUS=>	MnHBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|MEW2PVIoRjJyM{C1OlkzRC:jPh?=
BaF/3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLaNVAxKG6P	NHSwZo81QCCq		Mn7FTWM2OD14LkKgcm0>	MlnKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|MEW2PVIoRjJyM{C1OlkzRC:jPh?=
RPMI 8226	M{n6U2Z2dmO2aX;uJGF{e2G7	MkPxNlAhdk1?	NW\BNGtoQCCq		NVPQRpRbUW6mdXPld{BFVkFic4nueIhme2m\|	NXKxdXd2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0N\|YxPTBpPkG5OFM3ODVyPD;hQi=>
OPM2	NWPQW3NyTnWwY4Tpc44hSXO\|YYm=	MmXINlAhdk1?	MXO4JIg>		NUDseHpDW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl?	MoS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2M{[wOVAoRjF7NEO2NFUxRC:jPh?=
INA6	MW\GeY5kfGmxbjDBd5NigQ>?	M4O2W\|IxKG6P	M4nXRlghcA>?		MWrTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=>	NYHvOHZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0N\|YxPTBpPkG5OFM3ODVyPD;hQi=>
OPM1	NIK5dHZHfW6ldHnvckBCe3OjeR?=	NFfuTXgzOCCwTR?=	MXG4JIg>		NGDnWolUcWewaX\pZ4FvfGy7IHXubIFv[2W\|IF7GMe67SiCjY4Tpeol1gQ>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR\|NkC1NEc,OTl2M{[wOVA9N2F-
U266	NVjHd\|lvTnWwY4Tpc44hSXO\|YYm=	NE\aXIszOCCwTR?=	MlHmPEBp		MVHTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=>	NHfONYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUSzOlA2OCd-MUm0N\|YxPTB:L3G+
MM.1S	M3Sw[mZ2dmO2aX;uJGF{e2G7	MV6yNEBvVQ>?	NYDNelZQQCCq		MVPTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=>	M3vHVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NEO2NFUxLz5zOUSzOlA2ODxxYU6=
RPMI 8226	NHzK[HlHfW6ldHnvckBCe3OjeR?=	NH3yb4czOCCwTR?=	M1LY[VghcA>?		MXjTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=>	M4LZPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NEO2NFUxLz5zOUSzOlA2ODxxYU6=
CHLA-255	NVqzeVZKTnWwY4Tpc44hSXO\|YYm=	Mn\1NVAhdk1?	Mof6NlQhcA>?		NVjZb4NFVW:mZYP0cJkhemWmdXPld{Bk\WyuczDpckB1cGViR{CvS\|EheGijc3W=	Ml7CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4OEm2PFQoRjF5Nki5Olg1RC:jPh?=
NB-1691	M1KxOGZ2dmO2aX;uJGF{e2G7	NXGyTWJNOTBibl2=	M2DydVI1KGh?		MnL5V4lodmmoaXPhcpRtgSC{ZXT1Z4V{KGOnbHzzJIlvKHSqZTDHNE9IOSCyaHHz[S=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ6OU[4OEc,OTd4OEm2PFQ9N2F-
SK-N-AS	MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrKOI03OSEQvF2=	NGLaU4M4OiCq		M4D1XmlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyBzMDW=	Ml;EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4OEm2PFQoRjF5Nki5Olg1RC:jPh?=
CHLA-255	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfKOFIyKM7:TR?=	M37wflczKGh?		M1LrTGlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB{JR?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ6OU[4OEc,OTd4OEm2PFQ9N2F-
NB-1691	NHXOVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUj5PYdvOSEQvF2=	NYf4XlhUPzJiaB?=		NV3FUo5zUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEWl	M2TJW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5Nki5Olg1Lz5zN{[4PVY5PDxxYU6=
HKe-3	NEPwNWlCeG:ydH;zbZMhSXO\|YYm=	M{LkfFUxKG6P	NVSxd\|JLPDhiaB?=	MV\EUXNQ	M3TJcmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MnnOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ5N{ixO\|koRjF4N{e4NVc6RC:jPh?=
HCT116	NULseJljSXCxcITvd4l{KEG\|c3H5	M3PvOFUxKG6P	NXr0XlhpPDhiaB?=	M2TieGROW09?	NUPyNllvUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NVnF[WdVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3O\|gyPzlpPkG2O\|c5OTd7PD;hQi=>
T29Kt1	M4CxPGFxd3C2b4Ppd{BCe3OjeR?=	MUO1NEBvVQ>?	NV6yfY5WPDhiaB?=	NIfze49FVVOR	MlzCTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NHW4XVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNke3PFE4QSd-MU[3O\|gyPzl:L3G+
T29	MofkRZBweHSxc3nzJGF{e2G7	MXO1NEBvVQ>?	NUfySWk2PDhiaB?=	NEfkNWxFVVOR	MUDJcoR2[2W\|IHPlcIwh[XCxcITvd4l{	M3n2TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{e4NVc6Lz5zNke3PFE4QTxxYU6=
LNCap-Pro5	NXfSSY9tTnWwY4Tpc44hSXO\|YYm=	NUjQNJVCOSEQvF2=	NXH0[nhwPCCq	M3izfWROW09?	MkD5V5Ri[mmuaYrld{BxPTN?	MnriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTR4MUK1N\|IoRjF2NkGyOVMzRC:jPh?=
H460	MVPGeY5kfGmxbjDBd5NigQ>?	NGjnOmYyODBibl2=	MUKyOEBp	NXnQdVE2TE2VTx?=	NXTOeZk4UW6mdXPld{BIOi2PLYDoZZNmKGG{cnXzeEBidmRidIXieYxqdiCjc4PlcYJtgS2maYPhd5NmdWKueR?=	M4nGNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NkOxOlIxLz5zMk[zNVYzODxxYU6=
H322	NG\rTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DuZ\|ExKM7:TR?=	MVG3NkBp	MUPEUXNQ	MX3JR\|UxRTZ{MDDuUS=>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjZ\|MU[yNEc,OTJ4M{G2NlA9N2F-
H358	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIC4WVEyOCEQvF2=	MVq3NkBp	M2j4dGROW09?	MmXWTWM2OD15MDDuUS=>	NUX1OWNURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK2N\|E3OjBpPkGyOlMyPjJyPD;hQi=>
H460	MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWGxNEDPxE1?	NXfncm5oPzJiaB?=	NFXhXVNFVVOR	NHTndnNKSzVyPUGwNEBvVQ>?	MmnUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ4M{G2NlAoRjF{NkOxOlIxRC:jPh?=
RPMI8226/LR5	NIjsVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Moi1OVAxKG6pL33s	MoTsOFghcA>?	MlHYSG1UVw>?	NFixc25KdmirYnn0d{Bk\WyuIHfyc5d1cA>?	NXfXOGVMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK2N\|E3OTlpPkGyOlMyPjF7PD;hQi=>
U266/dox4	NHnDO4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zJVlUxOCCwZz;tcC=>	Mn7XOFghcA>?	M2PodGROW09?	Mle2TY5pcWKrdIOgZ4VtdCCpcn;3eIg>	MkL6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ4M{G2NVkoRjF{NkOxOlE6RC:jPh?=
U266/LR7	NIfqS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWO1NFAhdmdxbXy=	NY[zUlM4PDhiaB?=	MnPvSG1UVw>?	NVLQUHlQUW6qaXLpeJMh[2WubDDndo94fGh?	NFvBd4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMk[zNVYyQSd-MUK2N\|E3OTl:L3G+
WAD-1	NWTZeWt4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUG1NFAhdmdxbXy=	M1LNZlQ5KGh?	Mnf1SG1UVw>?	Ml;PTY5pcWKrdIOgZ4VtdCCpcn;3eIg>	NYrKfJk5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK2N\|E3OTlpPkGyOlMyPjF7PD;hQi=>
ARH77	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYO1NFAhdmdxbXy=	NH;5cmI1QCCq	MV3EUXNQ	NY[2fm1SUW6qaXLpeJMh[2WubDDndo94fGh?	NHTNWo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMk[zNVYyQSd-MUK2N\|E3OTl:L3G+
U266	M4TiT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PVR\|UxOCCwZz;tcC=>	NY[0U4JJPDhiaB?=	Mnr3SG1UVw>?	NVPRNlBiUW6qaXLpeJMh[2WubDDndo94fGh?	MoThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ4M{G2NVkoRjF{NkOxOlE6RC:jPh?=
H460	NXjyPVd[TnWwY4Tpc44hSXO\|YYm=	NEL4bGsyOCEQvF2=	MlXBNlQhcA>?	MmnxSG1UVw>?	MlHFTY5lfWOnczDCZ4wuOiCyaH;zdIhwenmuYYTpc44h[W6mIHPs[YF3[WenIHPvdpJmdGG2ZXSge4l1cCCJMj3NJJBp[XOnIHHydoV{fA>?	MnjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ2OUKxNVcoRjF{NEmyNVE4RC:jPh?=
UM-SCC-11B	M2\WVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TpRlExOCCwTR?=	M{HsZ\|czKGh?	NWHVSHBHTE2VTx?=	NU\4VYd6UW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTN3MEmxN{c,OTF\|NUC5NVM9N2F-
UM-SCC-9	NF3DU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\JZVExOCCwTR?=	M{\qO\|czKGh?	M17SfmROW09?	NYT1XW54UW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTN3MEmxN{c,OTF\|NUC5NVM9N2F-
B7E3	NVPxWYxHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnRNVAxKG6P	MYi3NkBp	MmnwSG1UVw>?	MYDJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTN3MEmxN{c,OTF\|NUC5NVM9N2F-
B4B8	Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLobXZbOTByIH7N	MVK3NkBp	NEDmXnhFVVOR	NV;MVmNZUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=	NWDYT2tKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzOVA6OTNpPkGxN\|UxQTF\|PD;hQi=>
PAM-LY2	NV\ueHNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYCxNFAhdk1?	MUK3NkBp	MWHEUXNQ	MmXjTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?	NFvnepc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUO1NFkyOyd-MUGzOVA6OTN:L3G+
PAM 212	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV2xNFAhdk1?	M3XYOFczKGh?	MWfEUXNQ	MXfJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?	NELKTpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUO1NFkyOyd-MUGzOVA6OTN:L3G+
PAM-LY2	NYnIe4hZTnWwY4Tpc44hSXO\|YYm=	M2XhNFExOCCwTR?=	NWTLdZh2OTJiaB?=	MXzEUXNQ	NETLOGJKdmirYnn0d{BPTi4QulKgZYN1cX[jdHnvci=>	NHfCeZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUO1NFkyOyd-MUGzOVA6OTN:L3G+
Hs Sultan	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXGxNFAhdk1?	NV7UUHV1PDhiaB?=	MlvBSG1UVw>?	MXLJR\|UxRTJyIH7N	NIDKbpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOwOlQ5QSd-MUGzNFY1QDl:L3G+
IM-9	NUHHOFM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LyXFExOCCwTR?=	NGDKOVA1QCCq	MX\EUXNQ	MXvJR\|UxRTZibl2=	M2fSfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{C2OFg6Lz5zMUOwOlQ5QTxxYU6=
U266	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2OyelExOCCwTR?=	NGjleY41QCCq	MXPEUXNQ	MlXjTWM2OD1\|IH7N	NYO0emJuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzNFY1QDlpPkGxN\|A3PDh7PD;hQi=>
LR5	Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPj[mRJOTByIH7N	NVrQSHp[PDhiaB?=	MVzEUXNQ	NHnpZmNKSzVyPUKwJI5O	M{X1R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{C2OFg6Lz5zMUOwOlQ5QTxxYU6=
MR20	NXjkVY05T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX:xNFAhdk1?	M{LCPVQ5KGh?	MmTqSG1UVw>?	NYPmOWVHUUN3ME2yNEBvVQ>?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTNyNkS4PUc,OTF\|ME[0PFk9N2F-
Dox40	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfHdnZzOTByIH7N	MVm0PEBp	MYnEUXNQ	MWnJR\|UxRTRyIH7N	NHzNWVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOwOlQ5QSd-MUGzNFY1QDl:L3G+
RPMI8226	Ml74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX[xNFAhdk1?	MnTxOFghcA>?	NFTVOoFFVVOR	NEnLbGdKSzVyPUOwJI5O	MlX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF\|ME[0PFkoRjFzM{C2OFg6RC:jPh?=
OVCA 429	M4PpT2Z2dmO2aX;uJGF{e2G7	MoTPN\|AxKG6P	MXW0PEBp	MVHEUXNQ	NEnsWHpFcXO{dYD0d{BqdnSjY4SgcZVtfGmlZXzseYxieiC2dX3vdkB{eGincn;p[JM>	NFzwfJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMEm5PVc3Pid-MUC5PVk4PjZ:L3G+
MCF-7	M1LoT2N6fG:2b4jpZ{BCe3OjeR?=	NUPwOYhGPTBizszN	M1fPVlQ5KGh?	M4P4WWROW09?	MUHLbYxteyClZXzsd{BjgSCvb4LlJJRp[W5iOUml	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODR7OU[0N{c,OTB2OUm2OFM9N2F-
FSCLL	Mle3R5l1d3SxeHnjbZR6KGG\|c3H5		Mn61NlQhcHK\|		NVztZnhVS0N3MDC9JFAvODB2IN88US=>	NXrWfmdYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG2N\|Q1OjlpPkKxOlM1PDJ7PD;hQi=>
HEK293	MWrDfZRwfG:6aXPpeJkh[XO\|YYm=		MkLwNlQhcHK\|		MleyR2M2OCB;IECuN\|Q4KM7:TR?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ\|NESyPUc,OjF4M{S0Nlk9N2F-
Glioma (HF2303)	NVHacm5PS3m2b4TvfIlkcXS7IHHzd4F6		NX36N4dMPzJiaILz		MVrFR\|UxKD1iMD6wNFA4KM7:TR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ6OE[5PUc,OjZ{OEi2PVk9N2F-
Glioma (HF2476)	NHmwboZEgXSxdH;4bYNqfHliYYPzZZk>		M1XwRlczKGi{cx?=		M3PJZ2VEPTBiPTCwMlAxODdizszN	NHO1SVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK4PFY6QSd-Mk[yPFg3QTl:L3G+
Glioma (HF2876)	MY\DfZRwfG:6aXPpeJkh[XO\|YYm=		MYe3NkBpenN?		M2XNd2VEPTBiPTCwMlAxODdizszN	M1;RXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mki4Olk6Lz5{NkK4PFY6QTxxYU6=
Glioma (HF2885)	M3Lme2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M4DGfFczKGi{cx?=		MonXSWM2OCB;IECuNFAxPyEQvF2=	M4HtdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mki4Olk6Lz5{NkK4PFY6QTxxYU6=
Glioma (HF3013)	MVLDfZRwfG:6aXPpeJkh[XO\|YYm=		NHy2O5M4OiCqcoO=		MYXFR\|UxKD1iMD6wNFA4KM7:TR?=	MmDuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OEi2PVkoRjJ4Mki4Olk6RC:jPh?=
Glioma (HF2381)	MkPxR5l1d3SxeHnjbZR6KGG\|c3H5		NIixW4g4OiCqcoO=		MnT5SWM2OCB;IECuNFAxPyEQvF2=	Mm\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OEi2PVkoRjJ4Mki4Olk6RC:jPh?=
Glioma (HF2790)	NWrnSXVKS3m2b4TvfIlkcXS7IHHzd4F6		NEHObnA4OiCqcoO=		NHjzd\|hGSzVyIE2gNE4xODB5IN88US=>	Ml\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OEi2PVkoRjJ4Mki4Olk6RC:jPh?=
HepG2	MX\DfZRwfG:6aXPpeJkh[XO\|YYm=		MmjvOFghcHK\|		MVXFR\|UxKD1iMD6wNUDPxE1?	NFLhfHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUiwNFgzPyd-Mkm4NFA5Ojd:L3G+
Molt4	NXHKN5dHTnWwY4Tpc44h[XO\|YYm=				NGfoRZJGSzVyIE2gNE4xOjFizszN	Ml7WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NEe1OFcoRjF6MkS3OVQ4RC:jPh?=
Molt4	MW\GeY5kfGmxbjDhd5NigQ>?				M3GxcWVEPTBiPTCwMlAzOSEQvF2=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjVyM{O0PUc,OjJ3MEOzOFk9N2F-
HL60	NFnkXnBHfW6ldHnvckBie3OjeR?=		NIf2NYsyOCCvaX7z		M3fneGVFPTBiPTCwMlAxOjVizszN	NGr1[3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUSyNlIxPid-MUm0NlIzODZ:L3G+
HL60	NH:yXIlHfW6ldHnvckBie3OjeR?=		M4PHXFExKG2rboO=		Mo\ZSWQ2OCB;IECuNFAzPSEQvF2=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl5M{GwNUc,OjF7N{OxNFE9N2F-
RPMI8226	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MmexS2k2OCB;IECuNFAxOjNizszN	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
CCRF-CEM	MnfES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MVnHTVUxKD1iMD6wNFA{PSEQvF2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
MDA-MB-435	MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NVf2XItUT0l3MDC9JFAvODByNESg{txO	MkDzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
MALME-3M	MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MnvIS2k2OCB;IECuNFAxPDVizszN	M{nqflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
NCI-H226	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NGfnbo1IUTVyIE2gNE4xODB2NjFOwG0>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
SK-MEL-28	Mnv2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NI\u[ZBIUTVyIE2gNE4xODB2NjFOwG0>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
A498	NX3PemdqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				Mn\ZS2k2OCB;IECuNFAxPDhizszN	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
MOLT4	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NHPofHRIUTVyIE2gNE4xODB3MTFOwG0>	NFvXb4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
OVCAR3	MmTpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				Mo\6S2k2OCB;IECuNFAxPTRizszN	NXT2WIN6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
SW620	M4XyR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7				M1XkWGdKPTBiPTCwMlAxODV3IN88US=>	NVH6eGtWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
MCF7	NYLNVGNMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NV;6S4l{T0l3MDC9JFAvODByNUWg{txO	MmraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
BT549	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NYDCbnd[T0l3MDC9JFAvODByNUWg{txO	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
UACC257	MoTPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MXTHTVUxKD1iMD6wNFA2QSEQvF2=	MmLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
SF539	MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NXzyVJRiT0l3MDC9JFAvODByNUmg{txO	NXW4ZlQ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
HCC2998	NUO4SZFMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				MVzHTVUxKD1iMD6wNFA3KM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
HCT116	MlvnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MmjJS2k2OCB;IECuNFAxPiEQvF2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
T47D	NGXKbW1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NVW1WpMzT0l3MDC9JFAvODByNjFOwG0>	NE\2PG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
CAKI-1	M1HyT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MkDPS2k2OCB;IECuNFAxPjZizszN	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
SK-MEL-5	NHL5flVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NUnmfYp1T0l3MDC9JFAvODByNkig{txO	MmHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
RXF393	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				Mn\uS2k2OCB;IECuNFAxPzFizszN	NIG4NVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
LOXIMVI	NX3BWoxDT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NEDMS3ZIUTVyIE2gNE4xODB5ODFOwG0>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
ACHN	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MmTLS2k2OCB;IECuNFAxPzlizszN	MlzFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
SR	NH3HZpFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MVHHTVUxKD1iMD6wNFA5PSEQvF2=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
UACC62	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NFzrNGJIUTVyIE2gNE4xODB7MTFOwG0>	NIDROXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
M14	NHuwfXpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NGDMZnJIUTVyIE2gNE4xODB7MzFOwG0>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
HT-29	MnHhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NUe5d3pPT0l3MDC9JFAvODByOUWg{txO	Mlj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
HOP92	Mnz5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NHvOXZhIUTVyIE2gNE4xODFizszN	MmfuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
NCI-H23	NEPSO5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				M4noWmdKPTBiPTCwMlAxOSEQvF2=	NV3hd2RxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
TK10	NXvtOopuT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				MlTVS2k2OCB;IECuNFAyKM7:TR?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
CEM	M{jzOGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MWK3NkBpenN?		MVHHTVUxKD1iMD6wNFEh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR2MUW4Nkc,Ojh2NEG1PFI9N2F-
U266	MUXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NW[zO3ZmPzJiaILz		NEfhdGpIUTVyIE2gNE4xODFizszN	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR2MUW4Nkc,Ojh2NEG1PFI9N2F-
Hs 578T	M3[1SGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NIjwSWFIUTVyIE2gNE4xODFyMjFOwG0>	NEnOUYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
UO31	Mm\wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MYHHTVUxKD1iMD6wNFExPSEQvF2=	MmjHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
SK-MEL-2	NEnscIxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NEXI[3FIUTVyIE2gNE4xODFyNzFOwG0>	NX\MVIJ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
SN12C	M2DwN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NUPOR5ptT0l3MDC9JFAvODBzMTFOwG0>	NXHHPVVsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
K562	NVj2PWM{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				M3T6UWdKPTBiPTCwMlAxOTF5IN88US=>	MoDPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
SF268	NEPkV\|lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MlPMS2k2OCB;IECuNFAyOTdizszN	NHu0cJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
COLO205	M1TSWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NETDUmNIUTVyIE2gNE4xODF{MzFOwG0>	MkCyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
MDA-MB-231	NEHUT\|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				M2LkTmdKPTBiPTCwMlAxOTJ4IN88US=>	M4rv[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
NCI-H522	M2LMcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NXe2RYFST0l3MDC9JFAvODBzNESg{txO	NFjRWXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
786-0	MlPxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MkLPS2k2OCB;IECuNFAyPDRizszN	MoDLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
MDA-MB-468	NYPy[YNkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NVfTbHVoT0l3MDC9JFAvODBzNEig{txO	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
HCT15	M{jISmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MUTHTVUxKD1iMD6wNFE2OSEQvF2=	M4HUbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
U251	NIH1VJNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				M4C0dGdKPTBiPTCwMlAxOTV3IN88US=>	NX23OVJZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
OVCAR5	MoTkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MlqxS2k2OCB;IECuNFAyPTVizszN	MmC4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
KM12	NXTHNVRyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				MXXHTVUxKD1iMD6wNFE4KM7:TR?=	MmTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
SF295	M4nISmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MYLHTVUxKD1iMD6wNFE4KM7:TR?=	M3\0RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
DU145	M3vlcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MVPHTVUxKD1iMD6wNFE4KM7:TR?=	M{PKfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
HL-60(TB)	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MXfHTVUxKD1iMD6wNFE6KM7:TR?=	NHr4d3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
OVCAR4	NFqxfmZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MmjhS2k2OCB;IECuNFAyQTVizszN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
SNB19	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MX7HTVUxKD1iMD6wNFIxPCEQvF2=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
SNB75	MkTaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NIHjXpVIUTVyIE2gNE4xODJyNDFOwG0>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
IGROV1	NIjsXFBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MmH6S2k2OCB;IECuNFAzOjRizszN	Mm\uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
OVCAR8	NVKxTpRlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NVj5VpJWT0l3MDC9JFAvODB{NkOg{txO	NHzJXVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
PC3	MlnmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				M4P5OWdKPTBiPTCwMlAxOjZ\|IN88US=>	NVPhfZhYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
EKVX	NEW3VpBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NVnLcJRrT0l3MDC9JFAvODB\|MEKg{txO	NFzoR\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
A549/ATCC	MlnLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MV3HTVUxKD1iMD6wNFMxQSEQvF2=	MmTYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
HOP62	M{iwbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MWfHTVUxKD1iMD6wNFQ1PyEQvF2=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
NCI-H460	M2HqOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				Mne1S2k2OCB;IECuNFA1PDdizszN	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
K562	MoD2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NWjHPHFYPzJiaILz		NE\KSZJIUTVyIE2gNE4xODdizszN	M{[wVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NESxOVgzLz5{OES0NVU5OjxxYU6=
NCI-ADR-RES	NIe3WpRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MlXiS2k2OCB;IECuNFEzOyEQvF2=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
SKOV3	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				Mnf5S2k2OCB;IECuNFE{QCEQvF2=	NGjZeZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
NCI-H322M	M2rD[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MmDqS2k2OCB;IECuNFE4QCEQvF2=	NHvMVIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
DLD1	MWfGeY5kfGmxbjDhd5NigQ>?		M3T2R\|YhcHK\|		M1;EdWlEPTBiPTCwMlAxODJizszN	NXjKUm5JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNFY5PjlpPkKyNlA3QDZ7PD;hQi=>
DLD1	NV:1cY1MTnWwY4Tpc44h[XO\|YYm=		Ml62OkBpenN?		MYLJR\|UxKD1iMD6wNFA6KM7:TR?=	MnryQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{ME[4OlkoRjJ{MkC2PFY6RC:jPh?=
HCT116	MXXDfZRwfG:6aXPpeJkh[XO\|YYm=		MkHHO\|IhcHK\|		MWHJR\|UxKD1iMD6wNFEh\|ryP	NYPQOVc{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2N\|QxOzlpPkK4OlM1ODN7PD;hQi=>
HCT116	MkXERY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MVq3NkBpenN?		NUDZbGdFUUN3MDC9JFAvODBzNDFOwG0>	NE\yOGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e2PVA{Oyd-Mke3OlkxOzN:L3G+
HepG2	NYXzfIhMSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NGrN[Y44OiCqcoO=		NEnI[IhKSzVyIE2gNE4xODF4MTFOwG0>	M{nN[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{[5NFM{Lz5{N{e2PVA{OzxxYU6=
SKOV3	NHz0em5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NGfvU5A4OiCqcoO=		Mn7hTWM2OCB;IECuNFAyPjJizszN	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd4OUCzN{c,Ojd5NkmwN\|M9N2F-
A2780	NF\PVYZEgXSxdH;4bYNqfHliYYPzZZk>				NFm0[pVKSzVyIE2gNE4xODF5IN88US=>	NUL1PXJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOFc2PDdpPkG4NlQ4PTR5PD;hQi=>
DOGUM	Mn\rR5l1d3SxeHnjbZR6KGG\|c3H5		MoTWO\|IhcHK\|		M{TzemlEPTBiPTCwMlAxOiEQvF2=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB\|MUW5NEc,OjNyM{G1PVA9N2F-
U266	NEXSPJlEgXSxdH;4bYNqfHliYYPzZZk>		MnT1O\|IhcHK\|		MmDkTWM2OCB;IECuNFAzPDVizszN	NX;kZWFtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1N\|c4OTZpPkG5OVM4PzF4PD;hQi=>
A549	NUHxTnBUSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NGK1UmM4OiCqcoO=		Ml[5TWM2OCB;IECuNFAzPSEQvF2=	NXHvc3c3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixPFI6QTBpPkK4NVgzQTlyPD;hQi=>
HL60	Mn3SRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXnGXGIxPzJiaILz		Mnz2TWM2OCB;IECuNFA{OiEQvF2=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF6Mkm5NEc,OjhzOEK5PVA9N2F-
RPMI18226	NHPaVW5EgXSxdH;4bYNqfHliYYPzZZk>		MnXmO\|IhcHK\|		M1TNcmlEPTBiPTCwMlAxOzVizszN	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB5N{[4NUc,OjFyN{e2PFE9N2F-
HL60	MkDJR5l1d3SxeHnjbZR6KGG\|c3H5		NWroXYpiPzJiaILz		MorLTWM2OCB;IECuNFA{PSEQvF2=	NU\vepVFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwO\|c3QDFpPkKxNFc4PjhzPD;hQi=>
RPMI8226	MYfDfZRwfG:6aXPpeJkh[XO\|YYm=		NUnIPYh[PzJiaILz		NUnRZnJqUUN3MDC9JFAvODB\|OEig{txO	NGfhdJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm2OVg3Pyd-Mk[5OlU5Pjd:L3G+
HL60	NGr5em1HfW6ldHnvckBie3OjeR?=		NXjZfZNnOiCqcoO=		NInDUJRKSzVyIE2gNE4xODRizszN	NVS2OFMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3OlkxOzNpPkK3O\|Y6ODN\|PD;hQi=>
U266	MYDGeY5kfGmxbjDhd5NigQ>?		M1PGW\|EhcHJ?		MoXsTWM2OCB;IECuNFA1KM7:TR?=	NXG1eG5SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OFE2QDJpPkK4OFQyPTh{PD;hQi=>
HL60	MlL6SpVv[3Srb36gZZN{[Xl?		NXr3eY9sOiCqcoO=		MWTJR\|UxKD1iMD6wNFQh\|ryP	MnH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4M{SwN\|koRjJ6NkO0NFM6RC:jPh?=
SEM	M4i5d2Z2dmO2aX;uJIF{e2G7		MoTpNkBpenN?		NIXCfGVKSzVyIE2gNE4xODR2MzFOwG0>	M2XJUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{[1PFkzLz5\|MEO2OVg6OjxxYU6=
HL60	NFXOSZJEgXSxdH;4bYNqfHliYYPzZZk>		MmPIO\|IhcHK\|		NVnYVIRqUUN3MDC9JFAvODB3NTFOwG0>	NIDzN4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUWzO\|cyPid-MUm1N\|c4OTZ:L3G+
U266	MoLvR5l1d3SxeHnjbZR6KGG\|c3H5		NVr2NpV5PzJiaILz		Ml;uTWM2OCB;IECuNFA2PzNizszN	MknaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NkW4OlcoRjJ4OU[1PFY4RC:jPh?=
MGC803	MV7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NHfFe2o4OiCqcoO=		M1TrcGlEPTBiPTCwMlAxPTd6MjFOwG0>	NEPmbVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e2PVA{Oyd-Mke3OlkxOzN:L3G+
GUMBUS	MorER5l1d3SxeHnjbZR6KGG\|c3H5		M1rke\|czKGi{cx?=		NWPFbpo4UUN3MDC9JFAvODB4IN88US=>	NHr1WFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CzNVU6OCd-MkOwN\|E2QTB:L3G+
ARH77	M3PjRmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MYC3NkBpenN?		MVjJR\|UxKD1iMD6wNFYxPyEQvF2=	NUHqPWgxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OlU5PjdpPkK2PVY2QDZ5PD;hQi=>
SW480	M4PrcWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MmHRO\|IhcHK\|		MXHJR\|UxKD1iMD6wNFYyKM7:TR?=	MlPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNUixPFQoRjJyMUW4NVg1RC:jPh?=
MDA-MB-231	MkTzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MXS3NkBpenN?		MXPJR\|UxKD1iMD6wNFY2KM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF6Mkm5NEc,OjhzOEK5PVA9N2F-
HL60	M1W3bGZ2dmO2aX;uJIF{e2G7		NYfJcHV{OiCqcoO=		MVnJR\|UxKD1iMD6wNFY3PyEQvF2=	M2X1fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{[1PFkzLz5\|MEO2OVg6OjxxYU6=
A549	MoKwR5l1d3SxeHnjbZR6KGG\|c3H5		MofBO\|IhcHK\|		M2TLVGlEPTBiPTCwMlAxPjdizszN	NFnvWWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG1PFE5PCd-MkCxOVgyQDR:L3G+
RPMI8226	NVqxfphYSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NILjS5c4OiCqcoO=		MYfJR\|UxKD1iMD6wNFY4KM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF6Mkm5NEc,OjhzOEK5PVA9N2F-
5TGM1	NHG3XZFEgXSxdH;4bYNqfHliYYPzZZk>		MXK0PEB1dyB5MjDodpM>		MlnQTWM2OCB;IECuNFA3PzhizszN	NHrHflg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGxPVU2QSd-MkSxNVk2PTl:L3G+
HL60	MlnVR5l1d3SxeHnjbZR6KGG\|c3H5		MYi3NkBpenN?		MV3JR\|UxKD1iMD6wNFY6KM7:TR?=	NX76[JZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OFc5OzJpPkG5O\|Q4QDN{PD;hQi=>
PC3	NIriZXNEgXSxdH;4bYNqfHliYYPzZZk>		M2jSRlczKGi{cx?=		M2PMZWlEPTBiPTCwMlAxPyEQvF2=	MmDpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNUixPFQoRjJyMUW4NVg1RC:jPh?=
DOGUM	NWnpdng3S3m2b4TvfIlkcXS7IHHzd4F6		NVfzNXNOPzJiaILz		M1PxdWlEPTBiPTCwMlAxPyEQvF2=	M{jvPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEOxOVkxLz5{M{CzNVU6ODxxYU6=
HL60	NF7NOIlEgXSxdH;4bYNqfHliYYPzZZk>		MnvUO\|IhcHK\|		NE[wWppKSzVyIE2gNE4xODdzIN88US=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF3OEG4OEc,OjBzNUixPFQ9N2F-
MKN45	MX7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NGCxXmw4OiCqcoO=		MnTmTWM2OCB;IECuNFA4OTVizszN	NVnKVIk3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3OlkxOzNpPkK3O\|Y6ODN\|PD;hQi=>
HepG2	Mkn0R5l1d3SxeHnjbZR6KGG\|c3H5		NIrrPW44OiCqcoO=		MYDJR\|UxKD1iMD6wNFc2KM7:TR?=	MoDSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNUixPFQoRjJyMUW4NVg1RC:jPh?=
HL60	M1fK[WFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M3fn[FczKGi{cx?=		NYjmeVJzUUN3MDC9JFAvODB5NjFOwG0>	MkXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5NkmwN\|MoRjJ5N{[5NFM{RC:jPh?=
RPMI8226	MVXDfZRwfG:6aXOgZYN1cX[rdImgZYdicW6\|dDDoeY1idg>?		NFzWSpA4OiCqcoO=		MkHxTWM2OCB;IECuNFA4QTZizszN	M{LMfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{[3PFE5Lz5{NEe2O\|gyQDxxYU6=
HL60	NF7oV3VEgXSxdH;4bYNqfHliYYPzZZk>		NV64[JBLPzJiaILz		NGfpcJBKSzVyIE2gNE4xODhizszN	NVnDVoJVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2N\|QxOzlpPkK4OlM1ODN7PD;hQi=>
MGC803	MorQR5l1d3SxeHnjbZR6KGG\|c3H5		MXO3NkBpenN?		NWfubJg2UUN3MDC9JFAvODB6IN88US=>	NFXTfZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[zOFA{QSd-Mki2N\|QxOzl:L3G+
SKOV3/TR	MUHGeY5kfGmxbjDhd5NigQ>?		M4Xy[\|Qh\GG7cx?=		MlTjTWM2OCB;IECuNFA5KM7:TR?=	NH7kVXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe2O\|k4Oyd-Mkm3Olc6PzN:L3G+
PC3	NFPWUIFEgXSxdH;4bYNqfHliYYPzZZk>		MkDpO\|IhcHK\|		M{TuZ2lEPTBiPTCwMlAxQDNizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB5N{[4NUc,OjFyN{e2PFE9N2F-
U266	MUnDfZRwfG:6aXPpeJkh[XO\|YYm=		NX;Sc\|MxPzJiaILz		MmnBTWM2OCB;IECuNFA5QCEQvF2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF3OEG4OEc,OjBzNUixPFQ9N2F-
RPMI8226	M4j3fmN6fG:2b4jpZ4l1gSCjc4PhfS=>				M2TxR2lEPTBiPTCwMlAxQDhizszN	MmXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB5Mke3OFYoRjJyN{K3O\|Q3RC:jPh?=
RPMI8226	MnniR5l1d3SxeHnjbZR6KGG\|c3H5		M1HOOVQ5KHSxIEeyJIhzew>?		MWjJR\|UxKD1iMD6wNFk2KM7:TR?=	NEjhUIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGxPVU2QSd-MkSxNVk2PTl:L3G+
ARH77	MY\DfZRwfG:6aXPpeJkh[XO\|YYm=		MnzZO\|IhcHK\|		MnPUTWM2OCB;IECuNFA6PTdizszN	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTl\|NEKxPEc,Ojl7M{SyNVg9N2F-
HEK293	MnX1SpVv[3Srb36gZZN{[Xl?		NFLQSo0{KGi{cx?=		NXe2W\|hnUUN3MDC9JFAvODFizszN	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh5NUezPUc,OjB6N{W3N\|k9N2F-
HCT116	NYriTIxvS3m2b4TvfIlkcXS7IHHzd4F6		MVi3NkBpenN?		MkL0TWM2OCB;IECuNFEh\|ryP	M4PDelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUS3O\|U4Lz5{M{W0O\|c2PzxxYU6=
NCI-H929	NEXXOWZEgXSxdH;4bYNqfHliYYPzZZk>		MYi3NkBpenN?		MVPJR\|UxKD1iMD6wNVA5PSEQvF2=	M2TyV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{[3PFE5Lz5{NEe2O\|gyQDxxYU6=
CCRF-CEM	NWr3NGRPSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M4LCPVczKGi{cx?=		NXz5ZmdnUUN3MDC9JFAvODFzIN88US=>	M3\aU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkOxNVYzLz5{NkKzNVE3OjxxYU6=
RPMI8226	M4\MWGN6fG:2b4jpZ4l1gSCjc4PhfS=>		M4jQc\|czKGi{cx?=		NVfjbXdXUUN3MDC9JFAvODFzMjFOwG0>	M1vmV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OUO0NlE5Lz5{OUmzOFIyQDxxYU6=
U266B1	MWnDfZRwfG:6aXPpeJkh[XO\|YYm=		NWK3TWVPPzJiaILz		M13kSGlEPTBiPTCwMlAyOTZ\|IN88US=>	M4TmW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OUO0NlE5Lz5{OUmzOFIyQDxxYU6=
BxPC3	NEjib4lEgXSxdH;4bYNqfHliYYPzZZk>		NV\KZWp4PzJiaILz		M17PTWlEPTBiPTCwMlAyOThizszN	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2N{izNkc,OTl5NEe4N\|I9N2F-
293T	MmLORY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXHSNIJPPzJiaILz		NUTuUW1jUUN3MDC9JFAvODF{IN88US=>	NWT0TopURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixPVE5PTBpPkK4NVkyQDVyPD;hQi=>
U266	NG\JcZNEgXSxdH;4bYNqfHliYYPzZZk>		M1rsT\|czKGi{cx?=		NXfUbVJNUUN3MDC9JFAvODF{MjFOwG0>	M3vjPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{S3PFMzLz5zOUe0O\|g{OjxxYU6=
SW480	MYXDfZRwfG:6aXPpeJkh[XO\|YYm=		NWr6c3dJPzJiaILz		MYjJR\|UxKD1iMD6wNVI{KM7:TR?=	NHvzbJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC3O\|Y5OSd-MkGwO\|c3QDF:L3G+
SKOV3	M2q0NGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NEHjVpg1KGSjeYO=		MnHTTWM2OCB;IECuNFEzQSEQvF2=	NWDTNZkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3Olc6PzNpPkK5O\|Y4QTd\|PD;hQi=>
A549	NYW5ZZFWS3m2b4TvfIlkcXS7IHHzd4F6		Moj2O\|IhcHK\|		NXf5V4FiUUN3MDC9JFAvODF\|OTFOwG0>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB5N{[4NUc,OjFyN{e2PFE9N2F-
HEK293	MYPGeY5kfGmxbjDhd5NigQ>?		NXnEOFVqOzBibXnudy=>		NVXtNng3UUN3MDC9JFAvODF2IN88US=>	NGTNNJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC0OFg1Pyd-MkGwOFQ5PDd:L3G+
RPMI8266	NGPLUpJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M1\pZ\|czKGi{cx?=		MkfaTWM2OCB;IECuNFE1PCEQvF2=	M4LpcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkOxNVYzLz5{NkKzNVE3OjxxYU6=
BxPC3	MoDaR5l1d3SxeHnjbZR6KGG\|c3H5		NIHFZ\|A4OiCqcoO=		MoHaTWM2OCB;IECuNFE3OiEQvF2=	M3nYcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUW4NVg1Lz5{MEG1PFE5PDxxYU6=
MDA-MB-231	MnLNRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NYLDbJVZPzJiaILz		MlfnTWM2OCB;IECuNFE3PjVizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd4OUCzN{c,Ojd5NkmwN\|M9N2F-
TOV21G	NF;BNVBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MmHTO\|IhcHK\|		NYT3R5dPUUN3MDC9JFAvODF4NzFOwG0>	M12wOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkOxNVYzLz5{NkKzNVE3OjxxYU6=
MDA-MB-231	NV:4UGc2S3m2b4TvfIlkcXS7IHHzd4F6		NHfRc2k4OiCqcoO=		NHTlS3lKSzVyIE2gNE4xOTdizszN	MmrQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4M{SwN\|koRjJ6NkO0NFM6RC:jPh?=
BxPC3	MmOxR5l1d3SxeHnjbZR6KGG\|c3H5		M4\5XVczKGi{cx?=		M3LqTmlEPTBiPTCwMlAyQTRizszN	MkHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyN{e2PFEoRjJzMEe3OlgyRC:jPh?=
HeLa	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2j4b\|czKGi{cx?=		Moi0TWM2OCB;IECuNFIh\|ryP	M33mXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NEK4NlQ2Lz5zOUSyPFI1PTxxYU6=
RKO	M{nrWmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NIPVdlg4OiCqcoO=		NYWyb4hKUUN3MDC9JFAvODJyODFOwG0>	Mnm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{M{GxOlIoRjJ4MkOxNVYzRC:jPh?=
MCF7	MljLRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NVTrZY5vOyCmYYnz		NYPxNlI5UUN3MDC9JFAvODJ3IN88US=>	NVrBfnR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1OzBpPkK4OVU4PDNyPD;hQi=>
Bel7404	M{[zS2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NHzabYU4OiCqcoO=		MnPaTWM2OCB;IECuNFI2ODRizszN	NYD4fIJyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3OlkxOzNpPkK3O\|Y6ODN\|PD;hQi=>
HepG2	NHTtOJJEgXSxdH;4bYNqfHliYYPzZZk>		NYHSNoVwPzJiaILz		NGex[lRKSzVyIE2gNE4xOjV{IN88US=>	NH3Cfos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC3O\|Y5OSd-MkGwO\|c3QDF:L3G+
HEK293	NFXJT2tHfW6ldHnvckBie3OjeR?=		NVHlUXlGOjRiaILz		Ml3oTWM2OCB;IECuNFI4KM7:TR?=	NW\Cd4xERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG2N\|Q1OjlpPkKxOlM1PDJ7PD;hQi=>
HCT116	M3\IUGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NU\YfIQyPzJiaILz		NHrkeWJKSzVyIE2gNE4xOjdizszN	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ\|MUG2Nkc,OjZ{M{GxOlI9N2F-
SUP-B15	NX;wOGZiTnWwY4Tpc44h[XO\|YYm=		NW\xcINiOiCqcoO=		MlzKTWM2OCB;IECuNFI5ODlizszN	NVrONIlMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOlU5QTJpPkOwN\|Y2QDl{PD;hQi=>
A431	M4\EUWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NFTrPJM4OiCqcoO=		NHzGT2RKSzVyIE2gNE4xOjh{IN88US=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ\|MUG2Nkc,OjZ{M{GxOlI9N2F-
A2780	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MVS3NkBpenN?		NUn1ZmttUUN3MDC9JFAvODJ6OTFOwG0>	M2S0N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUiyPVkxLz5{OEG4Nlk6ODxxYU6=
HL60	NYP4WXBlTnWwY4Tpc44h[XO\|YYm=		M4nrUFIhcHK\|		NEjOdoNKSzVyIE2gNE4xOyEQvF2=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd4OUCzN{c,Ojd5NkmwN\|M9N2F-
HL60	NFLMUW1HfW6ldHnvckBie3OjeR?=		MX:yJIhzew>?		M2fIVWlEPTBiPTCwMlA{KM7:TR?=	M{nyVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkO0NFM6Lz5{OE[zOFA{QTxxYU6=
HEK293	MlyxSpVv[3Srb36gZZN{[Xl?		NFvBdGc3KGi{cx?=		NIDtRmlKSzVyIE2gNE4xOyEQvF2=	MorLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7MUmzOFAoRjJ6OUG5N\|QxRC:jPh?=
WM266.4	MWXDfZRwfG:6aXPpeJkh[XO\|YYm=		NH7xNYo4OiCqcoO=		NXiwflRqUUN3MDC9JFAvODN3IN88US=>	MoHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{ME[4OlkoRjJ{MkC2PFY6RC:jPh?=
GUMBUS	Ml:xR5l1d3SxeHnjbZR6KGG\|c3H5		NIn4[lU4OiCqcoO=		NEf6O5RKSzVyIE2gNE4xOzVizszN	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB\|MUW5NEc,OjNyM{G1PVA9N2F-
HepG2	MXnDfZRwfG:6aXPpeJkh[XO\|YYm=		MojlO\|IhcHK\|		NIDOZ3JKSzVyIE2gNE4xOzd3IN88US=>	NEfob3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUWzO\|cyPid-MUm1N\|c4OTZ:L3G+
95-D	NG\Ic5VEgXSxdH;4bYNqfHliYYPzZZk>		MVq3NkBpenN?		NFjVc2NKSzVyIE2gNE4xOzhizszN	NULZ[ZNFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2N\|QxOzlpPkK4OlM1ODN7PD;hQi=>
95-D	MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWK3NkBpenN?		M1fh[WlEPTBiPTCwMlA{QDF6IN88US=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd4OUCzN{c,Ojd5NkmwN\|M9N2F-
SW480	MUXDfZRwfG:6aXPpeJkh[XO\|YYm=		Mmq5O\|IhcHK\|		M2XwfGlEPTBiPTCwMlA2KM7:TR?=	M2L5eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUO3O\|E3Lz5zOUWzO\|cyPjxxYU6=
KB	MkXCR5l1d3SxeHnjbZR6KGG\|c3H5		MY[3NkBpenN?		NYHvPItWUUN3MDC9JFAvODV7NTFOwG0>	MmPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3M{e3NVYoRjF7NUO3O\|E3RC:jPh?=
SKOV3	NYDKUY5pS3m2b4TvfIlkcXS7IHHzd4F6		NFzFTHA4OiCqcoO=		MnzuTWM2OCB;IECuNFY3QCEQvF2=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB5N{[4NUc,OjFyN{e2PFE9N2F-
SW1990	MlfSRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MVi3NkBpenN?		NG\F[ZlKSzVyIE2gNE4xPzlyNjFOwG0>	MljhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5NkmwN\|MoRjJ5N{[5NFM{RC:jPh?=
HeLa	MXjDfZRwfG:6aXPpeJkh[XO\|YYm=		NFzk[2w4OiCqcoO=		NX20PJZMUUN3MDC9JFAvODl{IN88US=>	M3\XelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUO3O\|E3Lz5zOUWzO\|cyPjxxYU6=
A549	NGrTR3NCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MWC3NkBpenN?		M1;pWmlEPTBiPTCwMlA6OiEQvF2=	MmexQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzOUG4OVAoRjJ6MUmxPFUxRC:jPh?=
H460	NVvFU4c6S3m2b4TvfIlkcXS7IHHzd4F6		MUi3NkBpenN?		Mk\4TWM2OCB;IECuNVE2KM7:TR?=	NXTyUVc4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1N\|c4OTZpPkG5OVM4PzF4PD;hQi=>
SKOV3	MXjDfZRwfG:6aXPpeJkh[XO\|YYm=		NHnjU244OiCqcoO=		NHXlN41KSzVyIE2gNE4yOyEQvF2=	NIrLOYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUWzO\|cyPid-MUm1N\|c4OTZ:L3G+
SKOV3	M4G1[mN6fG:2b4jpZ4l1gSCjc4PhfS=>		NEH4cmI4OiCqcoO=		M1jYS2lEPTBiPTCwMlE2OSEQvF2=	NGS5fIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG1PFE5PCd-MkCxOVgyQDR:L3G+
A549	MUfDfZRwfG:6aXPpeJkh[XO\|YYm=		MWK3NkBpenN?		M{fYb2lEPTBiPTCwMlI2PSEQvF2=	NH62UG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUWzO\|cyPid-MUm1N\|c4OTZ:L3G+
HL60	NVrtNJZkTnWwY4Tpc44h[XO\|YYm=		NYLLVXc6OiCqcoO=		MYrJR\|UxKD1iMD60OEDPxE1?	NFiy[nY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e2PVA{Oyd-Mke3OlkxOzN:L3G+
HL60	MWLGeY5kfGmxbjDhd5NigQ>?		MVGyJIhzew>?		M1nUc2lEPTBiPTCwMlQ1KM7:TR?=	M{DnRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkO0NFM6Lz5{OE[zOFA{QTxxYU6=
H460	MUPDfZRwfG:6aXPpeJkh[XO\|YYm=		MYW3NkBpenN?		MX;JR\|UxKD1iMD63PEDPxE1?	MlTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNUixPFQoRjJyMUW4NVg1RC:jPh?=
BGC823	M{j3OWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NWjDdWxxPzJiaILz		MXTJR\|UxKD1iMD64PEDPxE1?	NWHuV3R4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1N\|c4OTZpPkG5OVM4PzF4PD;hQi=>
MCF7	MnWwRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M3qyT\|czKGi{cx?=		NYPURppvUUN3MDC9JFE5NjN5IN88US=>	NFHjPYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSyOlYzQSd-Mkm0NlY3Ojl:L3G+
A549	MnX2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MUW3NkBpenN?		M4XoUmlEPTBiPTCyMlE{PTd\|IN88US=>	MlPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5NkmwN\|MoRjJ5N{[5NFM{RC:jPh?=
A549	NUnMdW9wS3m2b4TvfIlkcXS7IHHzd4F6		MnPzO\|IhcHK\|		M4LCe2lEPTBiPTCyMlE1KM7:TR?=	NGi4VoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[zOFA{QSd-Mki2N\|QxOzl:L3G+
BGC823	NF;mTmFEgXSxdH;4bYNqfHliYYPzZZk>		MVi3NkBpenN?		NHu0cJZKSzVyIE2gNk45QSEQvF2=	NIHWb2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0O\|g{Oid-MUm3OFc5OzJ:L3G+
MDA-MB-231	M{PrW2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MW[3NkBpenN?		Mn;WTWM2OCB;IEOuNVI2KM7:TR?=	MmjGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Mk[2NlkoRjJ7NEK2OlI6RC:jPh?=
BCG823	MnLGR5l1d3SxeHnjbZR6KGG\|c3H5		MmmzO\|IhcHK\|		NEPLc2xKSzVyIE2gN{4zQSEQvF2=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF3OEG4OEc,OjBzNUixPFQ9N2F-
A549	M2[0SGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYrFSnlKPzJiaILz		NHXHc4hKSzVyIE2gPU4{OThizszN	NGn3NG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSyOlYzQSd-Mkm0NlY3Ojl:L3G+
Calu6	M2HxNmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MkXDO\|IhcHK\|		M3[1XmxEPTBiPTCwMlAxPjFizszN	NG\qOXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi3OVc{QSd-MkC4O\|U4Ozl:L3G+
HEK293T	Mki2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M{PHUVQ5KGi{cx?=		NF\JfmRNSzVyIE2gNE4xOTZizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh2M{GwNEc,Ojl6NEOxNFA9N2F-
LO2	NXXjT5U5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NHjQWGs1QCCqcoO=		NWjsSFR5VEN3MDC9JFAvOzl6IN88US=>	MnnFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NEOxNFAoRjJ7OESzNVAxRC:jPh?=
NCI-H929	MVfDfZRwfG:6aXPpeJkh[XO\|YYm=		NYDMZ3c3PDhiaILz		M{j0PWxFPTBiPTCwMlAxPjZizszN	MlrZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N\|QoRjJ5OUm0O\|M1RC:jPh?=
U266	MUnDfZRwfG:6aXPpeJkh[XO\|YYm=		M2DD[FQ5KGi{cx?=		M1TmN2xFPTBiPTCwMlAyQCEQvF2=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOEc,Ojd7OUS3N\|Q9N2F-
LCL	M{j3XWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NIPpbFA1QCCqcoO=		MUPMSFUxKD1iMD6wNkDPxE1?	M1PrXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O\|M1Lz5{N{m5OFc{PDxxYU6=
MDA-MB-468	Mnj5R5l1d3SxeHnjbZR6KGG\|c3H5		MmX5OFghcHK\|		M4\ZUWxFPTBiPTCwMlA{PyEQvF2=	M1HDUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O\|M1Lz5{N{m5OFc{PDxxYU6=
RD-ES	M2TISWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NWfzcVdDPDhiaILz		NX7Ke2tEVER3MDC9JFAvODRizszN	MmHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N\|QoRjJ5OUm0O\|M1RC:jPh?=
WE68	MYHDfZRwfG:6aXPpeJkh[XO\|YYm=		Mn\zOFghcHK\|		M2DDSGxFPTBiPTCwMlEh\|ryP	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOEc,Ojd7OUS3N\|Q9N2F-
IMR90	NXHaOlI4S3m2b4TvfIlkcXS7IHHzd4F6		MlroOFghcHK\|		MXvMSFUxKD1iMD6xN{DPxE1?	NYjD[pQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzRpPkK3PVk1PzN2PD;hQi=>
KGN	M2PmcmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NWHIUnloPDhiaILz		NGGyOVRNTDVyIE2gNE4yQCEQvF2=	M1yyTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O\|M1Lz5{N{m5OFc{PDxxYU6=
HNDF	M3vncWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NIS0c\|A1QCCqcoO=		NYTncHliVER3MDC9JFAvPDhizszN	M4G0clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O\|M1Lz5{N{m5OFc{PDxxYU6=
MCF10A	M2rIeGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MmX4OFghcHK\|		NVfKdoZZVER3MDC9JFEvPSEQvF2=	NG\ySpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{PCd-Mke5PVQ4OzR:L3G+
SKOV3	NGTnNItEgXSxdH;4bYNqfHliYYPzZZk>		Mnr5OFghcHK\|		MW\MSFUxKD1iMT62JO69VQ>?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOEc,Ojd7OUS3N\|Q9N2F-
MCF7	NVX4T4pPS3m2b4TvfIlkcXS7IHHzd4F6		M1\He\|Q5KGi{cx?=		NHnSRWlNTDVyIE2gPU45KM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOEc,Ojd7OUS3N\|Q9N2F-
HL60	M1vkRmZ2dmO2aX;uJIF{e2G7	MkPnNVAxKG6P			NW\IbJFIUW6qaXLpeIlwdiCxZjDjbJlud3S{eYDzbY4udGmtZTDhZ5Rqfmm2eTDv[kBxem:2ZXHzc41mKGmwIHj1cYFvKEiONkCgZ4VtdHNiYYSgNVAxKG6P	MnrUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl4NUW3OlIoRjF7NkW1O\|YzRC:jPh?=
HeLa	MX7GeY5kfGmxbjDhd5NigQ>?	M2jnblUhdk1?	MkHSPEBpenN?		M4K4O2lvcGmkaYTpc44hd2ZicILveIVie2:vZTDhZ5Rqfmm2eTDpckBpfW2jbjDI[WxiKGOnbHzzJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjD1ZolyfWm2aX7HO\|ZXNU[OIILldI9zfGW{IHzleoVtKGG2IEWgcm0h[W[2ZYKgPEBpenNiYomgcJVkcW[ncnHz[UBie3OjeR?=	Mn7uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzOE[3PVQoRjJzMUi2O\|k1RC:jPh?=
HeLa	MX\GeY5kfGmxbjDhd5NigQ>?	NV:yWIx5OSC3TR?=	NUHzToxtQCCqcoO=		NXrtTJhsUW6qaXLpeIlwdiCxZjDwdo91\WG\|b33lJIFkfGm4aYT5JIlvKGi3bXHuJGhmVGFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJJVjcXG3aYTpcmc4PlZvRlygdoVxd3K2ZYKgcIV3\WxiYYSgNUB2VSCjZoTldkA5KGi{czDifUBtfWOrZnXyZZNmKGG\|c3H5	NVTZenU{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxPFY4QTRpPkKxNVg3Pzl2PD;hQi=>
LN229	M1XyVGZ2dmO2aX;uJIF{e2G7	MVyxNFAhdk1?	NW\zSWJnOSCqch?=		NX7tXndrUW6qaXLpeIlwdiCxZjDITWYy[WyyaHGg[ZhxemW\|c3nvckBqdiCqdX3hckBNVjJ{OTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhUEmILUHhcJBp[SCjY3P1cZVt[XSrb36gZZQhOTByIH7NJJBz\WmwY4XiZZRm\CCob4KgNUBpeiC3bnTldkBvd3Kvb4jpZUBkd26maYTpc44h\m:ubH;3[YQh[nliMkSgbJJ{KGmwY4XiZZRqd25idX7k[ZIhcHmyb4jpZUBkd26maYTpc44h[nliV3XzeIVzdiCkbH;0eIlv\w>?	NVPBTGc2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4N\|E3OzhpPkKxPFMyPjN6PD;hQi=>
LN229	NVe4TZNLTnWwY4Tpc44h[XO\|YYm=	M2nPcFIxKHWP	M1jzTVEhcHJ?		M1PV[WlvcGmkaYTpc44hd2ZiaInwc5hq[S2rbnT1Z4VlKEiLRkHhcJBp[SCjY3P1cZVt[XSrb36gbY4hcHWvYX6gUG4zOjliY3XscJMh[XRiMkCgeW0h[W[2ZYKgNUBpeiCycnXpcoN2[mG2aX;uJI1m[XO3cnXkJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	NXLYSldHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwN\|I3OzJpPkKyNFMzPjN{PD;hQi=>
U1	NW\UfHA1TnWwY4Tpc44h[XO\|YYm=	MYCxNEB2VQ>?	MmjDNlQhcHJ?		MYjJcohq[mm2aX;uJI9nKE6ILXvhdJBiSi2vZXTpZZRm\CC4aYLhcEBz\XCuaXPheIlwdiCrbjDIc41wKHOjcHnlcpMhMGi3bXHuLUBWOSClZXzsd{Bqdm[nY4Tl[EB4cXSqIGi0JJRzd3CrYzDITXYyKE6OND2zJIF1KDFyIIXNJIFnfGW{IEK0JIhzKGK7IGLUMXBEWiCjbnHsfZNqeyCrbjDwdoV{\W6lZTDv[kBVVkZvYXzwbIE>	MlP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{OUCwOVEoRjJ\|MkmwNFUyRC:jPh?=
Calu6	NEnqPHZHfW6ldHnvckBie3OjeR?=	MV:xNEB2VQ>?	NWT1[mx1OThiaILz		NGTHfnZKdmirYnn0bY9vKG:oIFjpd{11[WepZXSgSpJifGG6aX6gLJVvc26xd36gc5Jq\2mwKT;VZolyfWm2aX6gbY51\XKjY4Tpc44h\XiycnXzd4VlKGmwIHj1cYFvKEOjbIW2JINmdGy\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKG[{YYThfIlvKChzLUKxNEkheHKnY4Xyd49zKGyndnXsJIF1KDFyIIXNJIFnfGW{IEG4JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIHHuZYx6e2m\|	Mn\uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3ME[0PFYoRjJ\|NUC2OFg3RC:jPh?=
HCT116	M3H5[2Z2dmO2aX;uJIF{e2G7				NG\oVI5KdmirYnn0bY9vKG:oIIDyc5Rm[XOxbXWgbY4hcHWvYX6gTGNVOTF4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBw\iCyNUOgZpkhX2W\|dHXyckBjdG:2dHnu[{BidmGueYPpdy=>	NFLSV209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W0O\|c2Pyd-MkO1OFc4PTd:L3G+
HCT116	MnvFRZBweHSxc3nzJIF{e2G7				NFH2XFdKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gVGFTWCClbHXheoFo\SCkeTDX[ZN1\XKwIHLsc5R1cW6pIHHuZYx6e2m\|	Mn7aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NEe3OVcoRjJ\|NUS3O\|U4RC:jPh?=
HCT116	NIPOXIpE\WyuIHP5Z4xmKGG\|c3H5		MlztNlQhcHK\|		MoKxR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gTGNVOTF4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCJMj;NJJBp[XOnIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtd3diY4n0c41mfHKrYzDhcoFtgXOrcx?=	MlHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NEe3OVcoRjJ\|NUS3O\|U4RC:jPh?=
HEK293	NWT0VWxkS3m2b4TvfIlkcXS7IHHzd4F6	MnHyNE4xODBzIIXNJJRwKDFyMDD1US=>	NWHLWYpNPDhiaILz		NELUXoZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJTUt{OUOgZ4VtdHNiZYjwdoV{e2mwZzDteZJqdmViRlHQJIF1KDBwMECwNUB2VSC2bzCxNFAhfU1iYX\0[ZIhPDhiaILzJIJ6KEOnbHzUbZRmei2EbIXlJIF{e2G7	NEL6bo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W5OFI4OSd-MkO1PVQzPzF:L3G+
A549	NIjXfpdHfW6ldHnvckBie3OjeR?=	M{f6UFAvODJ3IITvJFAvPSC3TR?=	M1LDfVI1KGi{cx?=		NGjhSGpKdmS3Y4Tpc44hd2ZiY3XscEBl\WG2aDDpckBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDv[kBxd2y7LYXibZF2cXSrbnH0[YQheHKxdHXpcpMh[XRiMD6wNlUhfG9iMD61JJVOKGGodHXyJFI1KGi{czDifUBqdW23bn;icI91KGG\|c3H5	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ\|OUi2Nkc,OjV4M{m4OlI9N2F-
A549	MW\GeY5kfGmxbjDhd5NigQ>?	NF;6bYYxNjB{NTD0c{AxNjVidV2=	NInkeZYzPCCqcoO=		Mk\mTY5lfWO2aX;uJI9nKGOnbHyg[IVifGhiaX6gbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{B{fGGkaXzpfoF1cW:wIH;mJJA2OyCjdDCwMlAzPSC2bzCwMlUhfU1iYX\0[ZIhOjRiaILzJIJ6KGmvbYXuc4Jtd3RiYYPzZZk>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ\|OUi2Nkc,OjV4M{m4OlI9N2F-
A549	NVTYZ3FrTnWwY4Tpc44h[XO\|YYm=	NEXL[mYxNjB{NTD0c{AxNjFidV2=	MmPZNlQhcHK\|		M2jTbmlv\HWldHnvckBw\iClZXzsJIRm[XSqIHnuJIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMh[WOldX31cIF1cW:wIH;mJG5wgGFiYYSgNE4xOjVidH:gNE4yKHWPIHHmeIVzKDJ2IHjyd{BjgSCrbX31co9jdG:2IHHzd4F6	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ\|OUi2Nkc,OjV4M{m4OlI9N2F-
AMO1	Mk\ORY51cXS3bX;yJIF{e2G7	MmfMNUBu\y:tZx?=			M1LMPGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFHNU\|Eh[2WubIOgfIVvd2e{YX\0[YQhcW5iboXk[UBUS0mGIHLlbYdmKG2xdYPlJIF{e2W\|c3XkJIF{KHS3bX;yJIdzd3e2aDDpcohq[mm2aX;uJIF1KDFibXevb4ctKGm4IHHkcYlvcXO2ZYLl[EB1f2mlZTDw[ZIhf2Wnax?=	NITWT5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2OVY3Pid-Mk[1OlU3PjZ:L3G+
MCF7	MnPDSpVv[3Srb36gZZN{[Xl?	NUj0RnUyOzVibl2=	MUC0JIhzew>?		NVvNOVVmUW6qaXLpeIlwdiCxZjCyOnMheHKxdHXhd49u\SCrbjDoeY1idiCPQ1[3JINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjDobYdpKG2xbHXjeYxieiC5ZXnnbJQheG:ueYXibZF2cXSrbj3jc45rfWejdHXkJJBzd3SnaX7zJIF1KDN3IH7NJIFnfGW{IESgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	MkjTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N\|QoRjJ5OUm0O\|M1RC:jPh?=
MDA-MB-468	NV7repptTnWwY4Tpc44h[XO\|YYm=	NH\Vc5M{PSCwTR?=	M1K1OFQhcHK\|		M1Lvb2lvcGmkaYTpc44hd2ZiMk\TJJBzd3SnYYPvcYUhcW5iaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4YhcGmpaDDtc4xm[3WuYYKge4Vq\2i2IIDvcJl2[mmzdXn0bY4u[2:waoXnZZRm\CCycn;0[YlveyCjdDCzOUBvVSCjZoTldkA1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOEc,Ojd7OUS3N\|Q9N2F-
MDA-MB-231	M1XQV2Z2dmO2aX;uJIF{e2G7	M4C0VVEhfU1?			NVf6[oR5UW6qaXLpeIlwdiCxZjD0dplxe2mwIHzpb4Uh[WO2aY\peJkhd2ZiMk\TJJBzd3SnYYPvcYUh\GW{aY\l[EBnem:vIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XRiMTD1US=>	MnrTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OUGzOFQoRjJ6MkmxN\|Q1RC:jPh?=
MDA-MB-231	MonaSpVv[3Srb36gZZN{[Xl?	NXXYcXZsOSC3TR?=			MVXJcohq[mm2aX;uJI9nKGOjc4Dhd4UhdGmtZTDhZ5Rqfmm2eTDv[kAzPlNicILveIVie2:vZTDk[ZJqfmWmIH\yc40hcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDheEAyKHWP	Mmn3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OUGzOFQoRjJ6MkmxN\|Q1RC:jPh?=
MDA-MB-231	MlXySpVv[3Srb36gZZN{[Xl?	NUPrNFFWOSC3TR?=			NWS3SXNYUW6qaXLpeIlwdiCxZjDjbJlud3S{eYDzbY4hdGmtZTDhZ5Rqfmm2eTDv[kAzPlNicILveIVie2:vZTDk[ZJqfmWmIH\yc40hcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDheEAyKHWP	M4XzblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkmxN\|Q1Lz5{OEK5NVM1PDxxYU6=
SK-N-SH	NXLlNlJQS3m2b4TvfIlkcXS7IHHzd4F6	MkTTNE4yKHSxIEGgeW0>	NEjNWIIzPCCqcoO=		NG\1UWREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2QLWPIJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBifCByLkGgeI8hOSC3TTDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7	NVf0R5VWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyOlkzPTVpPkK5NlY6OjV3PD;hQi=>
MYCN2	MVzDfZRwfG:6aXPpeJkh[XO\|YYm=	NVzSWGE4OC5zIITvJFEhfU1?	NGr2UIQzPCCqcoO=		MlzKR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXlEVjJiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHH0JFAvOSC2bzCxJJVOKGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZk>	MnzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{NkmyOVUoRjJ7Mk[5NlU2RC:jPh?=
U266	MmHYRZBweHSxc3nzJIF{e2G7	NXrzfnBKOi53IH7N	MYmyOEBpenN?		NVz6[3pQUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDVNlY3KGOnbHzzJIF1KDJwNTDuUUBi\nSncjCyOEBpenNiYomgRY5v\XirbjDWM5Bzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dpk>	MmjjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|MESyPFQoRjJ7M{C0Nlg1RC:jPh?=
RPMI8226	NVGxcG9ESXCxcITvd4l{KGG\|c3H5	MX[yMlUhdk1?	MWKyOEBpenN?		MWfJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKFKSTVm4NlI3KGOnbHzzJIF1KDJwNTDuUUBi\nSncjCyOEBpenNiYomgRY5v\XirbjDWM5Bzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dpk>	Mn;tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|MESyPFQoRjJ7M{C0Nlg1RC:jPh?=
NCI-H929	NFSyW\|hCeG:ydH;zbZMh[XO\|YYm=	NXTmU\|g3Oi53IH7N	NHXUV3ozPCCqcoO=		MnTzTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCQQ1mtTFkzQSClZXzsd{BifCB{LkWgcm0h[W[2ZYKgNlQhcHK\|IHL5JGFvdmW6aX6gWk9xem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIJie2WmIH\sc5ch[3m2b33leJJ6	NUTiRZhrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzNFQzQDRpPkK5N\|A1Ojh2PD;hQi=>
TC32	NUDnd5pPeUiWUzDhd5NigQ>?				MkHCdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN?	MmjmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS	NHL5fGhyUFSVIHHzd4F6				MXHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	NHPNd489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	MYPxTHRUKGG\|c3H5				MVrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	NHjkdmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	MVTxTHRUKGG\|c3H5				NUnnV5QzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO=	Ml\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	MV;xTHRUKGG\|c3H5				MY\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	NH;US409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	NUn0cZJLeUiWUzDhd5NigQ>?				M1fxUpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	NFPiNY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	NW\RUpU{eUiWUzDhd5NigQ>?				MoThdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	NITVUGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	MmjPdWhVWyCjc4PhfS=>				NHi5PVNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=>	NGXpWGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	NXnHUmlQeUiWUzDhd5NigQ>?				NEfIe29yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	M{nz[JFJXFNiYYPzZZk>				NIjTV4ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	MnPZdWhVWyCjc4PhfS=>				MU\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	NYewWllIeUiWUzDhd5NigQ>?				NFPaXolyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-12	MoHVdWhVWyCjc4PhfS=>				M{CwOZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTF{IHPlcIx{	MofzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
fibroblast	NVTqV4xLeUiWUzDhd5NigQ>?				NGOxXXJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiY3;ueJJwdCCKaDD3bYxlKHS7cHWg[oljem:kbHHzeEBk\Wyucx?=	M4O1blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	MUfxTHRUKGG\|c3H5				MWnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDMRW4uPSClZXzsdy=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	NV72fGR{eUiWUzDhd5NigQ>?				NWXie3F2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	M3LCUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	NH[3cG1yUFSVIHHzd4F6				MVPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORk1GSmNzIHPlcIx{	NV;USXg2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	M1HE[ZFJXFNiYYPzZZk>				NWnU[4dOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO=	Mn3vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	NFHJWm5yUFSVIHHzd4F6				MmPLdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2VSDDj[Yxtew>?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh30	NF\kNWJyUFSVIHHzd4F6				M1vKeJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy\|	M2TsZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	NGGybIdyUFSVIHHzd4F6				NYDvb5JleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl?	Ml\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	MWHxTHRUKGG\|c3H5				MmrHdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRnQuOzdiY3XscJM>	MlHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	MYXxTHRUKGG\|c3H5				M2D0cZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG1IKDZ\|IDi2MXRIKFJrIHPlcIx{	M{fx[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30	M1L6eJFJXFNiYYPzZZk>				MWTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFMxKGOnbHzz	Mk\ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
fibroblast	NUfKSlY6eUiWUzDhd5NigQ>?				NFnFb3NyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBkd262cn;sJGhpKHerbHSgeJlx\SCoaXLyc4Jt[XO2IHPlcIx{	M2f3ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS	NEGyW4hyUFSVIHHzd4F6				M3SxNpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHUuOiCRUzDj[Yxtew>?	NUfKPIc5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	MUTxTHRUKGG\|c3H5				NXHkV3RVeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	MnG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	MkfSdWhVWyCjc4PhfS=>				M4TLXpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KE:{dHjv[49v[WxiM1Sgeoli[mmuaYT5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	NHq0dHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	NEnIWIRyUFSVIHHzd4F6				MnuzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=>	NWDGU4tYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	MUPxTHRUKGG\|c3H5				NXHtbIp3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWkRiY3XscJM>	MmHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Daoy	NW\NVWxbeUiWUzDhd5NigQ>?				NGSzepByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKESjb4mgZ4VtdHN?	NHr2UnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	NYDGUJI3eUiWUzDhd5NigQ>?				M1Xp[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KE:{dHjv[49v[WxiM1SgZ4F{eGG\|ZTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
TC32	Mn\DdWhVWyCjc4PhfS=>				NVzJO45DeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCWQ{OyJINmdGy\|	NED5XWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	NWTaVVZZeUiWUzDhd5NigQ>?				NVPjd\|RjeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	NEXBeWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	MoDPdWhVWyCjc4PhfS=>				MVjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	MV\xTHRUKGG\|c3H5				Ml3KdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	NE[xV2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	M{XkfJFJXFNiYYPzZZk>				NXHBU5lSeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	NYm4WZZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5	MVvxTHRUKGG\|c3H5				MUDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	M4nuW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18	MnvydWhVWyCjc4PhfS=>				NUfIfmp{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	M1jWZ5FJXFNiYYPzZZk>				MWjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORlE3PDNiY3XscJM>	NUnON4t2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	M2LoXZFJXFNiYYPzZZk>				Ml\VdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>?	Mk\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	MWXxTHRUKGG\|c3H5				M1vxdJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNLNUeETUKgZ4VtdHN?	MoW2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
TC32	NFr0dolyUFSVIHHzd4F6				M4TWUpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	M3KxWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh18	MWTxTHRUKGG\|c3H5				M{XRdpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOThiY3XscJM>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	NH3jOYxyUFSVIHHzd4F6				MknxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV4Fwey1{IHPlcIx{	M3mybFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	M1\Td5FJXFNiYYPzZZk>				MUjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHNLNUeETUKgZ4VtdHN?	NEjHNnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	MV7xTHRUKGG\|c3H5				MlvCdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohV3K2aH;nc45idCB\|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBTTCClZXzsdy=>	M{\m[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
HL60	MoDhSpVv[3Srb36gZZN{[Xl?	NWHRcoVwOSC2bzCxNFAhdk1?	NG\SXm0zPCCqcoO=		M1;BWmlvcGmkaYTpc44hd2ZicILveIVie2:vZTDpckBpfW2jbjDIUFYxKGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHPs[YF3\WRiUFHSVEBmgHC{ZYPzbY9vKGG2IEGgeI8hOTByIH7NJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0JIF{e2G7	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN4NUi5Nkc,OzB\|NkW4PVI9N2F-
SUP-B15	NInnNIpHfW6ldHnvckBie3OjeR?=	M4nBUFEhfG9iMUCwJI5O	M4XTTFI1KGi{cx?=		MljkTY5pcWKrdHnvckBw\iCycn;0[YF{d22nIHnuJIlu[XSrbnniMZJme2m\|dHHueEBpfW2jbjDTWXAuSjF3IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJINt\WG4ZXSgVGFTWCCneIDy[ZN{cW:wIHH0JFEhfG9iMUCwJI5OKGGodHXyJFI1KGi{czDifUBqdW23bn;icI91KGG\|c3H5	NF;WN2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO2OVg6Oid-M{CzOlU5QTJ:L3G+
SEM	M4[ySmZ2dmO2aX;uJIF{e2G7	NVv3XJNROSC2bzCxNFAhdk1?	MUmyOEBpenN?		NEnEepBKdmirYnn0bY9vKG:oIIDyc5Rm[XOxbXWgbY4hcHWvYX6gV2VOKGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHPs[YF3\WRiUFHSVEBmgHC{ZYPzbY9vKGG2IEGgeI8hOTByIH7NJIFnfGW{IEK0JIhzeyCkeTDpcY12dm:kbH;0JIF{e2G7	NV72V2RyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOlU5QTJpPkOwN\|Y2QDl{PD;hQi=>
SEM	MWrGeY5kfGmxbjDhd5NigQ>?	NEPiW4cyOCCwTR?=	M4PwXFE5KGi{cx?=		MYjJcohq[mm2aX;uJI9nKHC{b4TlZZNwdWViaX6gbJVu[W5iU1XNJINmdGy\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGGpZ4Lld49u\SCjY3P1cZVt[XSrb36gZZQhOTBibl2gZYZ1\XJiMUigbJJ{KGK7IHL5JGZCS1NiYX7hcJl{cXN?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN4NUi5Nkc,OzB\|NkW4PVI9N2F-
SEM	MoO3SpVv[3Srb36gZZN{[Xl?	MUmxNEBvVQ>?	M{XvelE5KGi{cx?=		NHLmV2FKdmirYnn0bY9vKG:oIIDyc5Rm[XOxbXWgbY4hcHWvYX6gV2VOKGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHHn[5Jme2:vZTDhZ4N2dXWuYYTpc44h[XRiMUCgcm0h[W[2ZYKgNVghcHK\|IHL5JIZtfW:{ZYPj[Y5k\SCvaXPyc5Nkd3CrYzDt[ZRpd2R?	M3naXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{[1PFkzLz5\|MEO2OVg6OjxxYU6=
HepG2	NVP4bIs2S2WubDD2bYFjcWyrdImgZZN{[Xl?				M{XaOGhmeEd{IHPlcIx{KH[rYXLpcIl1gSCzSGTTJIZweiCcaXvhJJZqenW\|IHnubIljcXSxcoO=	NFr3WVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|M{KyPVU1PSd-M{OyNlk2PDV:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-PERK / ATF-4; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against phospho-PERK, ATF-4. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. GRP-78 / GADD-34; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against GRP-78, and GADD-34. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. pro-caspase-12 / pro-caspase-3; PubMed: 15509775 Mol Cell Biol MEFs were treated with PS-341 for the indicated time periods, and the whole-cell extracts were prepared. Fifty-microgram aliquots of proteins were probed with polyclonal antibodies against caspase 12 and caspase 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. pro-caspase-9; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were pretreated with or without Tiron for 30 min and then treated with PS-341 for the indicated time periods. The whole-cell proteins were probed with polyclonal antibodies against caspases 9 and 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. p-IκBα / IκBα; PubMed: 20335171 J Biol Chem PS-341 induces IκBα degradation in human lung cancer cells. The given cells lines were treated with the indicated concentrations of PS-341 for 8 h (C). After treatment, the cells were then subjected to preparation of whole-cell protein lysates and subsequent Western blot analysis. COX-2 / cIAP2; PubMed: 24085292 J Biol Chem NCI-H157 cells were incubated with PS-341 (50 nM) or MG132 (20 μM) for the indicated times. Total cellular extracts were subjected to Western blot analysis for COX-2, cIAP2 and actin.	15509775 20335171 24085292
Immunofluorescence	Vimentin; PubMed: 19010849 Clin Cancer Res ES-2 ovarian cancer cells were incubated with 5nM PS-341, 10 μM NK84 or the combination of both for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). Ubiquitin; PubMed: 19010849 Clin Cancer Res IOSE-29 cells were incubated with 20nM PS-341 for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective).	19010849
Growth inhibition assay	Cell viability ; PubMed: 20571067 Mol Cancer Ther A, TSA enhanced the cell death induced by PS-341 in UMSCC1 cells. Cell viability was determined by the trypan blue exclusion assay. The assays were performed with triplicate samples, and the results are representative of three independent experiments (P < 0.01). Error bars depict standard deviation. B, C and D, TSA enhanced PS-341-induced cell death in UMSCC23 (B), UMSCC9 (C), and FaDu (D). P < 0.01.	20571067
ELISA	IL-8; PubMed: 24085292 J Biol Chem NCI-H157 cells were treated with PS-341 (10–100 nm) or TNF-α (10 ng/ml) as a positive control for 24 h. IL-8 concentrations in media were determined by ELISA. Data represent the mean ± S.D. of triplicates. **, p < 0.05 versus control cells. Results are representative of three separate experiments.	24085292

In vivo

The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. ^[2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. ^[3]

Protocol

Kinase Assay: ^[4]	- Collapse Kinetic Methods: In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λ_ex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research: ^[5]	- Collapse Cell lines: Human multiple myeloma cells line U266 Concentrations: ~10 μM Incubation Time: 2 days Method: The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: Human plasmacytoma xenografts RPMI 8226 Dosages: 1 mg/kg Administration: i.v. twice weekly for 4 weeks, then once weekly (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	76 mg/mL (197.79 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Bortezomib (PS-341) SDF

Molecular Weight	384.24
Formula	C₁₉H₂₅BN₄O₄
CAS No.	179324-69-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Velcade, LDP-341, MLM341, NSC 681239
Smiles	B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04656951	Not yet recruiting	Drug: Daratumumab	Multiple Myeloma	University of Cologne\|Janssen-Cilag G.m.b.H	April 2021	Phase 2
NCT04570631	Recruiting	Drug: Eftozanermin alfa\|Drug: Bortezomib\|Drug: Dexamethasone	Multiple Myeloma	AbbVie	November 5 2020	Phase 1
NCT03993262	Recruiting	Drug: Bortezomib\|Drug: Placebo	Autoimmune Encephalitis	Jena University Hospital	May 13 2020	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?
Answer:
S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Pan Proteasome Inhibitor

Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.
FDA-approved Proteasome Inhibitor

Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.
Newest Proteasome Inhibitor

Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.
Classic Proteasome Inhibitor

ONX-0914 (PR-957) : Selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

Related Proteasome Products

VR23 ^New

VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.
Calpeptin ^New

Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively. Calpeptin attenuates apoptosis and intracellular inflammatory changes in muscle cells.
Marimastat (BB-2516) ^New

Marimastat (BB-2516, TA2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.
MG-132

MG132 (Z-Leu-Leu-Leu-al) is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 μM and 1.2 μM for the inhibition of proteasome and calpain, respectively. MG132 activates autophagy and induces apoptosis in tumor cells.
Carfilzomib (PR-171)

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities. Carfilzomib activates prosurvival autophagy and induces cell apoptosis.
Ixazomib (MLN2238)

Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and K_i of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Ixazomib (MLN2238) induces autophagy. Phase 3.

Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.
ONX-0914 (PR-957)

ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).
Ixazomib Citrate (MLN9708) Analogue

Ixazomib Citrate (MLN9708) Analogue is the analogue of Ixazomib Citrate (MLN9708) from WO2016165677A1. Ixazomib Citrate (MLN9708) immediately hydrolyzed to Ixazomib (MLN2238), the biologically active form, on exposure to aqueous solutions or plasma. Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/K_i of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Ixazomib (MLN2238) induces autophagy. Phase 3.

Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.
Celastrol (NSC 70931)

Celastrol (NSC 70931, Tripterine) is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway. Celastrol inhibits dopaminergic neuronal death of Parkinson's disease through activating mitophagy.

Features:A potent antioxidant and anti-inflammatory drug.
Oprozomib (ONX 0912)

Oprozomib (ONX 0912, PR-047) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Choose Your Country or Region

By Signaling Pathways

By product type

Bortezomib (PS-341)